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Abstract of thesis entitled: 
A Computational-Based Drug Development Framework 
Submit ted by TSE, Ching Man 
for the degree of Master of Philosophy 
at The Chinese University of Hong Kong in September 2011 
The process of drug development is slow and costly, especially in 
discovering a good drug candidate. Computat ional methods are 
at t ract ing attent ion due to its efficiency and cost effectiveness 
and have contr ibuted to several drug discoveries. I t has been 
serving as a supplementary method because the experimental 
process is inefficient and expensive. Since current methods are 
ad hoc and independent, we have developed a comprehensive 
framework for the drug development process. 
i 
The Interactive Drug Discovery and Design framework (IDS) 
consists of three major modules: Screening and Analysis, De-
sign and Refinement, Interaction and Visualisation. Screening 
is first performed to determine i f a protein is a viable drug tar-
get which can be used to cure disease. Algor i thms in the design 
module generate suitable compounds for further studies. A user 
optimises and verifies the drug candidates using the interaction 
module. 
The screening and analysis module matches a protein target 
to clusters of annotated proteins based on the protein function. 
A novel representation for structural analysis, heterogeneous 
vector, is developed to facilitate the representation of proteins 
and measuring their similarities. This novel method performs 
2 times better than well-established methods in clustering pro-
tein according to their functions. For function classification, 
heterogeneous vector performs 40% better than many existing 
approaches. 
ii 
The design and refinement module optimises a synthetic com-
pound produced in the previous modules which is used to inter-
act w i th the protein target, enhancing or repressing its function. 
Evolut ionary algori thm is deployed to generate a set of drug can-
didates and their affinities are determined by energy calculation. 
The design process mimicked the natural chemical reaction that 
the result ing compound is more likely to be useful. Our imple-
mentat ion on the design algori thm produced 10% better results 
in aff inity and its execution t ime is around half of the latest 
approach. 
The interaction and visualisation module guides a user in 
investigating a drug candidate to verify its effectiveness. The 
interface projects the structure of molecules in a v i r tua l reality 
environment and provides supporting information. Assisted by 
the interface, the design and refinement module can produce 
drug candidates having a further 20% better aff inity w i t h human 
intelligence. 
iii 
The developed framework provides integrative solution for 
targeted drug design. The drug candidates created using our 
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This chapter introduces the importance of drug discov-
ery. Some drug discovery methods and the motivat ion 
in performing this research are discussed. 
A l though we enjoy the convenience l iv ing in the cities, we 
also face exceptionally strong diseases emerging in the recent 
decades. Many existing medicines are no longer effective against 
many kinds of bacterial infections. In particular, v i ra l infection 
1 
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is a major threat that most medicines have no effect. Whi le there 
are breakthroughs in targeted therapy in treat ing cancers, the 
process in discovering a new targeted drug is slow and costly. I t 
is v i ta l to facil itate the process of drug discovery for curing and 
preventing new diseases. The drug discovery process consists of 
several phases: identifying suitable drug candidates, laboratory 
experiments and then clinical trials. The laboratory experiments 
and clinical tr ials are mandatory in evaluating the efficacy and 
side effects of the drug candidates. I t is extremely important to 
discover or develop a suitable drug candidate otherwise costly 
efforts in the other phases are wasted. 
Find ^ Design drugs Evaluate & Visualise & 
drug targets「specifically rank verify 
I f n 
Iteratively optimise 
Interact 
Figure 1.1: A flowchart about our framework developed 
In this thesis, we have developed a framework providing a 
comprehensive solution to drug discovery and design. In figure 
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1.1, the flow of the framework is briefly i l lustrated. The elements 
in the flowchart w i l l be introduced in the following sections. 
1.1 Obtain information on drug targets 
Before designing a drug, i t is essential to obtain information 
about the target a drug can interact. Many diseases are caused 
by viruses or bacteria which we do not have much knowledge. 
Using sequencing techniques, we can discover some information 
about the proteins in the bacteria or viruses which are viable 
drug targets. However, in most cases, only the sequence of pro-
tein is available which wi l l not give researchers any clue on the 
functions of the proteins. In addition, the structures of v iral 
proteins are essential for analysing the effectiveness of a drug on 
the protein targets. Resolving the structure of a v i ra l protein 
using X-ray crystallography, a technique to take photographs 
on proteins, is expensive. Thus, the functions and structures 
of proteins are often inferred using computational techniques. 
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Nevertheless, some current protein function prediction methods 
have discrepancy in modelling which are not compatible w i th 
one another. Besides, the definition of protein function in some 
methods is not standardised, rendering these methods not very 
useful. There are two other commonly used methods relying 
on the availabil ity of experimental data. One method considers 
protein domains, the annotated regions of proteins which can 
exist, evolve and function independently. The other method 
studies homologous proteins that their protein structures have 
been resolved. The protein sequence of the homologous proteins 
is similar to the protein queried. The availabil ity of experimen-
tal data on protein domains and resolved protein structures is 
relatively scarce compare to the amount of protein sequences. 
We thus propose to introduce an algori thm which can operate 
on easily obtainable data, the secondary structure of a protein, 
and produce comparable results to the more complicated meth-
ods. 
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We shall introduce an algori thm using a novel protein repre-
sentation called heterogeneous vector which is used to describe 
proteins for efficient comparison in the screening and analysis 
module to identi fy the protein functions. This heterogeneous 
vector makes use of the secondary structures and motifs of pro-
tdns to achieve compact representation and efficient compari-
son. The vector can also be util ised in many existing clustering 
and classification algorithms. Experiments on clustering and 
classification show that using this vector achieves superior per-
formance comparing to current algorithms, the proposed algo-
r i t hm is 2 times better in clustering and 40% better in classifi-
cation. 
1.2 Drug Design 
Once the protein target is identified, a common practice to pro-
duce in i t ia l drug candidate is through screening, which tests a 
large number of compounds at a t ime under the same experimen-
CHAPTER 1. INTRODUCTION 25 
ta l setting for a biological target. The screening method elim-
inates those compounds that cannot interact w i th the desired 
protein. The problem is the screening approach checks a large 
amount of compounds at the same time. A l l compounds must be 
prepared chemically and steps to remove non-interacting com-
pounds can be hazardous. A computational approach, known 
as v i r tua l screening, has been introduced to mimic the chemi-
cal experiment wi thout actually ut i l ising any chemical materi-
als- A major drawback is the inabi l i ty to model every exper-
imental parameters such that the screened results may not be 
the same as the chemical counterpart. Also, the libraries used 
in the screening approach contains only the compounds known 
in the first place and thus i t does not create new compound 
which may be more effective. Recently, the research community 
performs an addit ional step by mix ing and appending existing 
compounds to form new compounds. The mix ing procedure 
can be further differentiated into fragment-based and diversity-
CHAPTER 1. INTRODUCTION 7 
oriented approaches[1] and relevant computat ional techniques 
are available [2]. The fragment-based approach creates a l ibrary 
of small fragments, which are light-weighted compounds w i th 
specific effects, and novel compounds are constructed using the 
l ibrary[3, 4] by appending the fragments to a compound scaf-
fold. The diversity-oriented approach, however, constructs the 
l ibrary using basic elements such as single atoms [5，6]. The 
fragment-based approach produces compounds which are more 
l ikely to have medical effectiveness and can be synthesised while 
the diversity-oriented approach is able to create a larger variety 
of compounds. There are computational algorithms to model 
the fragment-based[7, 8] and atom-based[9, 5, 10] approaches. 
Whi le the computational algorithms are not as accurate as 
their experimental counterpart, i t continues to attract attention 
owing to the effectiveness and the advantage of reducing the 
number of experiments. Several factors have to be addressed 
before the computational approaches can be accepted by the 
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biomedical experts in drug development. One major factor is 
the accuracy of the current tools is not high enough and unsta-
ble because the evaluation of drug aff inity is diff icult to model. 
Many tools focus only on the physiochemical property of the 
drug candidates while addit ional information such as the func-
tions of the drug target can be useful in designing the com-
pounds is often overlooked. Based on these issues, we introduce 
a knowledge-driven drug design algorithm, SmartGrow, which 
puts constraints over the fragment-based design process using 
molecular weights and drug-likeliness knowledge for the design 
and refinement modules. The SmartGrow contains a genetic 
algori thm to create mult iple configurations of drug candidates 
for a docking program. The evaluation function of the genetic 
algori thm is used to assess the affinities of drug candidates. Ex-
tensive experiments against the state-of-the-art approach show 
an average of 30% faster execution t ime and produce drug can-
didates that are 10% better in affinity. 
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1.3 Interface for interaction 
To further enhance the capabil i ty of the design algori thm and 
veri fying the design of drug candidates, human intelligence is 
incorporated in the interaction and visualisation module. There 
are researches report ing the benefit of studying proteins in a 
v i r tua l reality environment [11] and achieving better results us-
ing interaction in docking[12]. We have developed an interface 
in displaying the drug candidates from the design module and 
their protein targets on a v i r tua l reality environment. There are 
mult ip le display modes to visualise different levels of details of 
the drug candidate and the protein target The interface assists 
the user w i t h information, such as interacting atoms, for inter-
action. By adding the interactive element to the design module, 
compared w i th the algori thm wi thout interaction, resulting drug 
candidates are 9% better in aff inity and the program runs 20% 
faster than the non-interactive counterpart. 
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1.4 Summary 
Whi le there are many tools which study different areas of the 
drug discovery process, they are usually independent and diffi-
cult to integrate. In this research, we have developed a com-
prehensive drug development framework to address the short-
comings of the current algorithms. We have integrated available 
data into the drug discovery process, refined its algorithms and 
improved the qual i ty of the protein databases. The addit ional 
information used includes drug target information, its function 
and related interaction which can be uti l ised to estimate the 
aff inity in the screening and analysis module. Mul t ip le protein 
databases are integrated and cross-validated to remove redun-
dancy and increase confidence. We have also constructed an 
improved drug design algorithm, achieving higher accuracy and 
efficiency for a drug target in the design and refinement module. 
To counter the di伍culty in evaluation, we incorporate human 
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intelligence to the design process, supported by an interactive 
a lgor i thm in the interactive and visualisation module. 
The rest of the chapters are organised as follows. Chapter 2 
contains the background studies on protein funct ion predict ion 
algori thms and drug design algorithms Visual isat ion techniques 
used in drug design and protein analysis are also discussed in 
chapter 2. Chapter 3 gives a brief overview of the algorithms 
we proposed. I n chapter 4，we explain our proposed compact 
data representation, heterogeneous vector, for prote in s imi lar i ty 
and prote in funct ion predict ion. I n chapter 5, an improved drug 
design algor i thm, SmartGrow, we have developed is explained. 
I n chapter 6, we discuss our V R interface to veri fy and interact 
w i t h the drug design process. The last chapter is the conclusion. 




This chapter wi l l provide a background study on drug 
discovery, including generation of drug candidates and 
accessing affinity. Researches related to funct ion pre-
dict ion and interaction analysis of proteins are also in-
cluded. 
In the recent decade, the need to search for more compounds 
as drug candidates continues to grow because diseases are more 
12 
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diff icult to cure these days. A common practice to discover ini-
t ia l drug candidates is to screen a l ibrary of known compounds. 
Nevertheless, out of the possible configurations of the molecules 
which may have drug properties, only a small proport ion of the 
molecules were synthesised, evaluated and exploited[13]. There 
can be many useful compounds which have not been explored 
but attempts in synthesising these compounds can be costly. 
I t is impor tant to discover drug candidates in an efficient way. 
Computat ional drug discovery tools are employed due to lower 
cost and higher efficiency than their laboratory counterparts. 
Computat ional methods have successfully leaded to the discov-
ery of several NDA-approved drugs [2'. 
There are several factors that affect the effectiveness of drug 
discovery tools. The major factors include knowledge about the 
drug targets, the number of drug candidates and the evaluation 
quality. I f the drug targets are known, drug candidates can be 
designed specifically for these targets such that the resulting 
CHAPTER 2. BACKGROUND STUDY 14 
drugs are more effective and have less side effects. Since drug 
targets are usually proteins, to determine whether a protein is 
a suitable target, the function of a protein is often analysed. 
For newer diseases, although we may know that some proteins 
are involved in the process, their functions may not have been 
discovered. Thus, we have to rely on protein function prediction 
methods to give insight on whether a protein is suitable as a drug 
target. 
Af ter a drug target is identified, the next step in drug dis-
covery process is to design a drug that interacts w i th the target. 
The computational methods in drug design are modelled similar 
to their laboratory counterparts. First, an in i t ia l drug candidate 
is screened against the drug target by measuring their binding 
affinity. The drug candidate is then optimised by appending 
fragments of compounds, which wi l l increase its binding aff inity 
to its target. Since the computational methods perform this op-
t imisat ion virtual ly, a large number of drug candidates can be 
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generated. The chance of gett ing a suitable drug candidate is 
higher when more candidates are being evaluated. Some other 
methods emphasise on the geometric and chemical properties of 
the drug target to design a specific drug candidate. More details 
are given in the following section Drug Design. 
When the drug design program generates a drug candidate, 
researchers wi l l want to visualise the result to gain insights about 
the feasibil ity of the interaction and synthesisability of the drug 
candidate. Sometimes researchers wi l l also use visualisation to 
check whether there is a direct interaction between a drug can-
didate and its target, even if the interaction is determined using 
laboratory experiments. In addition, visualising the drug can-
didates and their targets provides a p lat form for the researchers 
to interact, which can improve the evaluation quality. There 
are articles report ing the benefits of the interactive approach 
in achieving better solutions in bioinformatics. We wi l l discuss 
more about protein function prediction, drug design and visual-
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isation in biomedics in the following sections. 
2.1 Protein Function Prediction 
A protein is presented by its composition of amino acids, which 
are its basic bui lding blocks. In human, there are 20 types of 
amino acids, also known as residues, which create almost all 
the proteins we found. When every residue is represented by 
a character, a protein can be represented by this sequence of 
characters. Identif ication of suitable proteins as drug targets 
is increasingly important for targeted therapy. A good under-
standing of protein function and the role in biological process 
is essential to evaluate the effectiveness as a drug target. There 
are different interpretations on protein function. The major i ty 
consensus of the protein functions can be found in Protein Data 
Bank ( P D B ) [ 1 4； . 
The Protein Data Bank is a database that stores protein 
structures found using laboratory experiments. The P D B is a li-
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bra iy of 3-dimensional (3D) structure of proteins, containing co-
ordinates resolved using laboratory experiments. This database 
also contains protein sequence information and functional re-
gion of proteins annotated by biological experts. This l ibrary 
provides information for many structure-based analysis, which 
is important for protein function prediction and essential for 
drug design. A screenshot of the PDB describing protein 3A〇K 
is provided in figure 2.1. 
I n figure 2.2, different representations of a protein is illus-
trated. A protein can be considered as a composition of amino 
acids. I n the figure on the left, each character represents an 
amino acid and the whole sequence represents the protein. Thus, 
a protein can be represented by a str ing of 20 different charac-
ters. This character str ing representation enables easy compu-
tat ional analysis. 
The figure in the middle shows the secondary structures of 
a protein. Secondary structures are local segments of proteins 
CHAPTER 2. BACKGROUND STUDY 18 
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Figure 2.1: A screenshot of the Protein Data Bank 
which are more stable due to hydrogen bonds among residues. 
Some combination of residues form certain geometric shapes 
such as alpha helices and beta strands. We refer to these geo-
metric shapes, the secondary structures. I n the figure, the alpha 
helices are represented using ribbons and beta strands are rep-
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春（T 
Protein Sequence (residue) Secondary Structure (fold) Protein with Binding Pocket 
Figure 2.2: Examples of concept in bioinformatics: (left) Sequential represen-
tation of protein in amino acid (middle) Cartoon representation of secondary 
structures of protein (right) Binding site on a protein 
resented using flat strips. The secondary structure of a protein 
gives clues to its overall shape in 3D. 
The figure on the r ight gives a simplified representation of 
the protein surface and its binding site. Based on energy min-
imisation, the residues sequence wi l l fold into a 3D shape close 
to a sphere. The roughness on the surface of proteins provides 
places for interaction, where the pockets are potential binding 
sites. From the different representations of proteins, information 
about the composition of amino acids, the shape of protein and 
the pockets on proteins can be extracted. Protein function pre-
dict ion algorithms usually rely on these information to perform 
prediction. 
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Protein function prediction algorithms are generally sequence-
based or structure-based. Most sequence-based methods are 
pattern-based which a profile using hidden Markov model ( H M M ) 
is constructed. A profile refers to a particular amino acid se-
quence which is short and shared across mult iple types of protein 
in many species. 
Sequence-based predictors use sequence-search algori thm to 
discover similar proteins w i th known functions. The sequence 
of the protein to study is compared against a set of protein 
sequences, using substring search and alignment. The sequence 
regions which are similar may have functional relationship. The 
state-of-the-art sequence-search algori thm is BLAST[15]. This 
algori thm compares the proteins by matching each amino acid 
to discover a high-score segment. Given the score of matching, 
a particular pair of amino acid is Sij. The probabi l i ty of f inding 
an amino acid on protein i is Pi, which is random across all 
positions. The expected score for two random amino acids wi l l 
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be PiPjSi j . The normalised score for a high-score pair is 
of XS-\nK o = , 
In 2 ‘ 
where A and K are two calculable parameters. Statist ically, the 
posit ions of amino acid result ing in high-score pair tend to occur 
w i t h target frequency, given by 
Qij = PiPj 
B L A S T uses these scores and frequencies to compute a scoring 
matr ix，which represents the best matching positions of amino 
acids. 
There are also newer methods such as HHsearch[16] which 
uses H M M to describe patterns for comparison. Using a H M M 
model, amino acids have correlation w i t h the adjacent amino 
adds which models better than position-specific score in B L A S T . 
The score in HHsearch is calculated using log-sum-of-odds, which 
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represents the ratio of probabil i ty of f inding a protein sequence 
using an H M M and wi thout H M M . The log-sum-of-odds score 
is given by 
S⑴—log ... ,xl\ emissiononpath) 
P{xi,... ,xl\ Null) , 
where X i , . . . , is a protein sequence of length L. The numera-
tor is the probabi l i ty from the H M M and the denominator is the 
probabi l i ty of a random model. Some of the profiles are defined 
in the 3D structures and stored in several databases including 
Pfam[17] and PR0SITE[18] . These profiles are also called pro-
t d n domains which are special that they can exist, evolve and 
function independently. 
Structure-based methods make use of functional clues from 
protein structure to predict their functions. These methods are 
considerably more accurate than the sequence-based methods. 
Proteins carrying similar functions usually have similar shapes, 
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also called folds. Some prediction methods uses fold match-
ing as a crucial step in the function prediction. Ear ly meth-
ods compare the structures such as DALI[19], GRATH[20] and 
secondary structure alignment [21] where recent methods oper-
ate on the residue template including TM-align[22]. A l l these 
methods require the coordinate files of proteins which record the 
3-dimensional shape of the proteins. D A L I uses distance matr ix 
approach to compare the amino acids in proteins A and B. In 
the distance matr ix , all pairwise scores of the amino acids are 
calculated which means an amino acid in protein A is compared 
w i t h all the amino acids in protein B. The distance matrices 
represents the contact patterns, which are predefined geometric 
shapes in a certain orientation, between two proteins. The ma-
trices are optimised on minimising the intramolecular distance 
to find out similar fold region, or substructures of the proteins. 
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« 
The score of fold region is given by 
i=l j=l 
where i and j indicate pair of macthed amino acids and L is 
the tota l number of pairs. The function 0 is a similari ty mea-
sure based on pairwise relationship. The similari ty measure can 
be further differentiated into r igid and elastic scores. The r igid 
score represents the predefined structural patterns and the elas-
tic scores is used to search for the largest common substructure 
between two proteins. The r igid score is given by 
卞，J) 二沪一 1 4 一 d引， 
where is a c o n s t a n t ,略 df j are matched amino acids in the 
distance matrices of proteins A and B respectively. The elasitc 
score, which is more tolerant against gradual geometric distor-
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t ion, is given by 
( X 
0 0，力叫 \ 乂 , 
沪， Z = J 
J 
where is the average of df^ and df^ and is a constant. The 
funct ion w is an exponential function to normalise the elastic 
score. D A L I first performs greedy search for predefined pattern, 
for example a consecutive of 6 amino acids, and calculate the 
distance matrices. D A L I then performs Monte Carlo optimisa-
t ion to discover better pair. The probabi l i ty is accept the move 
is p = exp(^ * 一 S)) where S丨 is the new score and S is the 
old score. This algori thm repeats unt i l the score is no longer 
improved. G R A T H is a graph theory based algori thm which 
represents proteins using the network terminology. A 'node, is a 
vector representations of the secondary structure types using the 
label only, where the label is either alpha-helix or beta-strand. 
'Edges' are the distance and angle difference between the vec-
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tor representations. This algorithm generates two matrices on 
the types of secondary structure and geometric information. I t 
first matches whether the types of secondary structure match 
between two proteins. Then i t checks the difference on the ge-
ometric information is w i th in a given tolerance. Consider two 
proteins have SSI and SS2 number of secondary structures and 
a tota l of R1 and R2 amino acids respectively. The largest sim-
ilar region, which has the same types and number of secondary 
structure, has a size of CS. W i t h i n the region, protein 1 has 
C R l number of amino acids and protein 2 has CR2 number of 
amino acids. Given weight factors W^ = + + W^, the 
score between the two proteins is given by 
Q 一 ^^Max{SSl,SS2) 
Optimising the tolerance for distance and angles results in dif-
ferent scores between the two proteins which can identi fy the 
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opt imal similar region. TM-a l ign improves over the distance 
matrices by using rotat ion matrices which achieve higher ac-
curacy and efficiency. TM-a l ign first refines protein regions 
of secodnary structures which consists of alpha-helicies, beta-
strands. A l though the simi lar i ty between secondary structure 
is binary, i.e. 1 or 0，between two amino acids on two proteins, 
this a lgor i thm computes a consecutive 6 amino acids to obtain 
an average. The regions of the proteins are assigned to either 
alpha-helix or beta-sheet i f 
— A，)| < 5 气 i ; fc = 2，3，4) 
is satisfied for al l distances dj,j+k between j t h and { j + A;)th 
amino acids. The parameters 入 and 沪⑷ are some constants. 
Using the in i t ia l s imi lar i ty assigned, the proteins are rotated to 
reduce the intermolecular distance between the proteins. The 
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score similar i ty matr ix is defined as 
卵 j\ _ 1 
l + dl/doiLminr 
where is the distance between amino acid i in protein 1 and 
amino acid j in protein 2. The parameter L—n is the length 
of the smaller protein, in number of amino acids, and do is a 
function to normalise the effect of the protein length. Through 
repeated rotat ion and computation of the score, the proteins are 
rotated to opt imal positions that the similar regions overlap. 
Other than the shape, some aspects of the protein, partic-
ularly pockets and clefts, are important clues to its function. 
Methods on searching similar pockets such as pvSoar[23], Surface[24 
and ef-site[25] have been developed to discover local substruc-
tures of proteins. Searching similar pockets requires the use of 
defined pockets and void from PDB. The web service pvSoar 
compare the query pattern w i th the known protein structure 
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databases using the protein sequence and substructure similar-
i ty to spot local structural similarities. This algor i thm obtains 
the simi lar i ty score of protein sequences in the form of E-value 
using B L A S T and the structural simialr i ty is calculated using 
Root Mean Squared Deviat ion (RMSD). Given two different pro-
teins V and w, their RMSD is given by 
\ n 
\ i=l 
where Vi and Wi are the coordinates of two amino acids on pro-
tein V and w respectively. The RMSD sums all the distances 
of amino acid pairs and normalises the result. Since RMSD 
is sensitive to displacement of the proteins as i t considers only 
the distances, pvSoar employed two RMSD metrics. The pv-
Soar named the the conventional RMSD as coordinate RMSD 
(cRMSD), which measures the similar i ty between substructure 
using distances. The pvSoar introduced a new metric on RMSD 
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called orientation RMSD (oRMSD). Using oRMSD, the pockets 
of a protein, identified by comparing w i th predefiend patterns, 
is projected onto a unit sphere and then the usual RMSD is cal-
culated. The Surface is a web service which focuses on f inding 
local structural similarities which could be a region of functional 
amino acids. The Surface performs an addit ional step over pv-
Soar that i t also compares the substructure w i t h PROSITE to 
retrieve the functional annotations, which label the functions of 
regions on the proteins. In their algorithm, they developed a 
local surface comparison method which is independent of the 
protein sequence or the overall shape. For each amino acid, i t 
is replaced by a more compact representation using two point 
coordinates, going through the centre of the amino acid and the 
connection point w i th other amino acids. The distances among 
all amino acids are calculated using RMSD. The algori thm starts 
by choosing the closest pairs, and expand towards nearby amino 
acid i f the RMSD distance is w i th in threshold. Thus, a re-
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gion of amino acids which are close together is marked as local 
substructure and compared w i th the protein domain database 
PROSITE. The th i rd method ef-site also focuses on identi fying 
local region of proteins but focus more on the properties of f u n o 
t ional sites. The ef-site algori thm employs manual inspection 
which computes the surface of the query protein and highlights 
area of interest according to surface geometry and electrostatic 
properties. 
Should the protein target possesses novel structure, structure-
based methods wi l l not work well. The algorithms on structure-
based analysis all rely on the existence of coordinates informa-
t ion of proteins. Whi le they can achieve better result ut i l ising 
this information, their tests are restricted to the availabil i ty of 
data and usually have high computational complexity unless a 
compact representation is used. These algorithms often per-
form an all-to-all comparison on the amino acids between two 
proteins. To analysis the proteins wi thout explicit structure 
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information, there are data mining approach[26] and machine 
learning techniques[27, 28, 29, 30] to predict the function. These 
approaches often employ learning algorithms such as artif ical 
neural network (ANN) and support vector machine (SVM) to 
create a predictor using known associations as training data. 
In the algorithm uti l ising ANN, the authors chose around 30 
features to t ra in the neural network. The features include the 
20 types of amino acids, the secondary structure types such as 
alpha-helix and beta-strand, 6 types of pocket structures and 
2 types of frequency counts against reference databases. Their 
t raining process is kept tracked that the predictor does not over-
fit using the Matthews Correlation Coefficient. Af ter the neural 
network is bui l t , the authors performed clustering on the amino 
acids according to their spatial distances. They evaluated the 
significance of the results using 2:-score, which is given by 
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where P。and Pr are the observed and expected frequencies 
of correct results of the predictions. Using this machine learn-
ing approach wi thout expl ici t ly calculating the simi lar i ty in se-
quence or the structure, they have correctly predicted the func-
tions for around 70% of the proteins in their dataset. The other 
approaches adopt S V M in their predictors, which are trained 
using bo th positive data set and negative data set. The posi-
t ive data set contains the correct associations of proteins and 
their functions. The negative data set contains the incorrect as-
sociations and usually has more entries than the positive data 
set. To apply protein information in the t ra in ing process of the 
predictor, the protein is encoded by a vector x which includes 
amino acid composition, secondary structure and other chemi-
cal properties. I n SVM, i t aims to find a kernel funct ion which 
modifies the vectors of data points such that the vectors from 
the positive and the negative data sets are further separated. In 
30], the authors use one of the common kernels Gaussian kernel 
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which is given by 
K { x i , x j ) = exp-"工广工』2/2— 
where x i and Xj are the vector representations of two proteins. 
The protein function predictor is bui l t on this kernel and the 
decision is made using this equation. 
/Or) = sign oPiyiK{x, Xi) + 
The parameters a? and b are determined by maximising a Lan-
grangian expression 
I 1 / z 
^i^jViVj^ixi, Xj) 
i=l i=l j=l 
under the conditions: 
I 
aiVi = 0 
i=l 
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The funct ion f { x ) computes a number which can be positive or 
negative. A positive value means that the protein represented by 
the vector x is predicted to belong to the positive class, and vice 
versa. They have evaluted the performance of their predictor 
using Matthews Correlation Coefficient. They have also tested 
on proteins which are similar in structures but different functions 
that they are able to predict the functions correctly for 62.5% 
of the proteins. 
To achieve highest performance, sequence-based methods and 
structure-based methods are combined to form a consensus, us-
ing mult ip le predictors, and published as web services such as 
ProFun[31] and IntFold[32]. They are usually a package of mul-
t iple prediction algorithms which has similar purposes to those 
we have discussed. ProFun indeed is a collection of methods 
we have discussed including DAL I , SURFACE, ef-site and etc. 
The IntFold provides more comprehensive information includ-
ing domain annotations, function prediction, estimated struc-
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ture and binding site prediction. For IntFold, they there are 
modules named nF〇LD4, DISOclust 2, DomFOLD, FunFOLD 
1 and ModFOLD 3 to perform structure prediction, disorder 
prediction, domain prediction, function prediction and model 
quali ty analysis respectively. 
Al though there are a large number of algori thm developed 
to predict the functions of proteins, most of the algori thm in-
cluding the machine learning methods require knowledge in the 
3-dimensional structure of the proteins. W i t h respect to the 
number of protein sequences, the amount of studied protein 
structures is few. We hence have developed a compact vector 
representation for proteins to ultil ise the protein sequences, and 
the information derived. By employing a vector representation, 
we can apply machine learning techniques to construct the pro-
tein function predictor. In addition, we have developed a novel 
similari ty measure to compare both positional information and 
secondary structure types together. Thus, we name our vector 
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representation - heterogeneous vector, indicating that we pro-
cess posit ional information and structural informat ion together. 
2.2 Drug Design 
Targeted therapy is increasingly attract ive owing to the effec-
t ive and less side effects. For each drug target, i t is neces-
sary to design a drug specifically for the target. The drug is 
designed to hamper the functional i ty of the target or trigger 
immune response of the host. The design techniques include 
fragment-based and diversity-oriented to generate drug candi-
dates for laboratory experiments[1] and related computational 
techniques are developed[2]. Other techniques such as physics-
based approaches have achieved good accuracy. Physics-based 
approaches use thermodynamic integration[33, 34] which achieve 
accurate free-energy prediction at the expense of computational 
complexity. In performing thermodynamic analysis, the Gibbs 
free energy AG of the ligand-protein system is calculated, where 
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a lower AG means the interaction between the l igand and the 
protein is stronger. The binding aff inity Ka of the l igand-protein 
system is defined as 
Ka 二 e x p - A G / R T 
where R is the gas constant and T is the absolute temperature. 
The Gibbs free energy is in t u rn given by 
AG = AH - TAS 
I n this equation, AH is the enthalpy of the system which re-
flects the strength of the interaction between the l igand and the 
protein，while AS is the entr ipy which reflects changes in shapes 
of the l igand and the protein. There are many models on the 
Gibbs free energy for drug candidates analysis and often avail-
able in simulation packages. The method described in[33] uses 
molecular simulat ion GROMOS96 to model the interact ion be-
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tween the drug candidates and the target. Since the interaction 
is modelled as a particle system, the computat ional cost is very 
high that is not suitable for large scale screening. The other 
physics-based method in[34] only uses thermodynamics to opti-
mise the structure of drug candidates only, but does not use i t 
to model the interaction of the drug candidates and the protein 
target. For a normal drug, its hydrophobicity is low so that i t 
is soluble in water and can be easily absorbed. In addit ion, the 
drug should be flexible to adapt to changes in binding site, oth-
erwise i t is highly susceptible to drug resistance. The authors 
in [34] use thermodynamic analysis to check the condit ion of 
hydrophobici ty and flexibility. 
Structure-based approaches enable wider diversity and a lower 
computat ional cost. Fragment-based growing strategies[3, 4], 
which create novel structures by adding interacting moieties 
to an in i t ia l scaffold, are generally more popular than molec-
ular simulation due to its lower computational expense and the 
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Figure 2.3: Procedure of fragment based growing: fragments are repeatedly 
added to the initial scaffold 
higher degree of diversity. 
In figure 2.3, the procedure of constructing drug candidates 
using fragments is i l lustrated. In the first step, an in i t ia l lig-
and is decided. A possible way to select the in i t ia l l igand is to 
screen the known compounds for the drug target. Compounds 
which have high affinities on the drug target can be selected as 
the in i t ia l ligands. Therefore, the derived drug candidates from 
this compounds are more likely to possess high affinity. How-
ever，since the in i t ia l ligands are fixed, there is less diversity in 
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generating new candidates. 
Another way is to choose a pr imi t ive compound w i t h very 
few atoms. This way ensures opportunit ies to generate a wider 
range of drug candidates. I t is possible that the in i t ia l choice is 
unsuitable which reduces the effectiveness of the design process. 
Af ter the in i t ia l l igand is decided, a fragments l ibrary needs to 
be prepared. The fragments l ibrary contains small compounds 
which can be easily produced and large compounds which have 
functions. A fragment is randomly selected and appended to the 
the in i t ia l l igand randomly to generate drug candidates. Mul-
t iple drug candidates are produced by appending different frag-
ments. These drug candidates are then evaluated using a scoring 
function. A scoring function is usually derived from known drug-
target interaction and simplified thermodynamic models. I n the 
i l lustrated algori thm in figure 2.3, screened drug candidates are 
used as the in i t ia l l igand for a new generation. The drug candi-
dates can be further optimised in this way by appending more 
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fragments. 
Many algorithms such as P R O - L I G A N D , SPROUT, L U D I 
and Groupbui ld use fragment-based strategies to produce de 
novo structures[35, 36，37, 10]. Some methods including G R O W 
take into account of the structural informat ion of the receptor [38 . 
Using the target's geometry as a constraint, the design process 
is l imi ted to the scope of the target b inding site. I n addit ion, 
G R O W does not use the growing strategy we have discussed. 
I n G R O W , several fragments are first placed in the b inding 
site of the protein target. These fragments are then jo ined to-
gether using pre-defined rules to complete the l igand. Evolut ion-
ary algori thms (EAs) are also employed to enhance diversity of 
structures[5, 6]. E A has the advantage of the natura l selection 
process which avoids exhaustive search of de novo drug candi-
dates. E A also guarantees newly generated drug candidates w i l l 
not be worse than previously evaluated ones. 
However, most of the fragment-based approaches we men-
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t ioned do not account for the flexibility of the ligands, resulting 
in inaccurate results in many situations. A recent approach, 
AutoGrow, addresses the issue by incorporating a docking algo-
r i t hm into fragment growing techniques [39]. A docking program 
is a molecular simulation which makes use of prior knowledge 
to predict the preferred orientation of a ligand on the protein. 
AutoGrow is one of the drug design algorithms which uses a 
fragment-based growing strategy but also considers f lexibi l i ty of 
the drug candidates. AutoGrow also applies genetic algorithm 
to produce mult iple configurations of drug candidates for further 
laboratory studies. 
Although AutoGrow has been considering the flexibility of 
the ligand in the interaction w i th the protein target, i t does not 
assess the chemical properties of the generated ligands which are 
essential towards drug absorption. In our developed algorithm 
SmartGrow which is improved over AutoGrow, we have incorpo-
rated rule-based filters to check the properties of the generated 
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ligands. The ligands which cannot pass the fi lter are removed 
before evaluated using the docking program which is a compu-
tat ional ly expensive process. 
2.3 Visualisation and Interaction in Biomedic 
As the modell ing of an experimental environment cannot be 
complete and computationally expensive, there are attempts 
to incorporate human intelligence to facil itate the process. To 
Facilitate human intervention requires effective data presenta-
tion. There are many attempts to combine visualisation to study 
biomedical problems. Visualisation is useful in presenting com-
plex protein information such as the locations of protein domains 
and the shape of protein in 3D. One example is given previously 
that visualisation can be used to inspect binding pockets. There 
are also advanced viewers, PyMol and JMol，to display the co-
ordinates files of proteins from PDB. The viewer can study the 
shape, structure and surface of proteins using these viewers. 
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Visual isat ion is further uti l ised as the p la t fo rm for users to 
interact. Th is technique has been introduced to help solving two 
complex problems, protein docking and drug design. 
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Figure 2.4: The user interface of Molecule Evoluator 
I n figure 2.4，the interface of a drug design tool, Molecule 
Evoluator, is shown. The drug design too l Molecule Evoluator[40' 
uses atom-based evolut ionary approach to explore mul t ip le con-
f igurations of drug candidates. This too l displays numerous con-
figurations in 2D for the user to choose f rom and to modify, as 
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shown in figure 2.4. The user can modify the drug candidate 
atom-by-atom. The evaluation however depends on the user, 
requiring the user's extent of knowledge on Chemistry. In addi-
t ion, when the protein target is available, the tool cannot take 
advantage of this piece of information by estimating their inter-
action. 
Al though i t is possible to display drug candidates in 2D, pro-
teins are far too complex to have efficient representations in 2D. 
To get a better sense of depth information, research was made to 
display the proteins in v i r tua l reality, part icular stereoscopy[H . 
In this work, the researchers studied comparative visualisation 
on the proteins and discussed the advantages. There is a short-
coming in their visualiser that i t does not support the standard 
PDB format. There are attempts to combine v i r tua l reality and 
visualisation to achieve better result in some biomedical prob-
lems. There is also an attempt to perform protein docking called 
VRDD[12]. In their model, the user guides a l igand towards the 
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binding site of the protein target in a v i r tua l reality (VR) en-
vironment. The V R environment provides immersive sense of 
depth and distance which is essential in guiding and investigat-
ing a l igand on its protein target A t the same time, their system 
provides real-time feedback to aid the user. Their system re-
quires the user to control the whole process for the algori thm to 
work. 
In this thesis, we have modelled a similar interface to ac-
complish the effect of V R D D . Instead of modell ing upon the 
inferface upon a docking program, our interface is modelled to 
accommodate the drug design algori thm SmartGrow. Through 
the interface, a user can perform manual inspection and guide 
the procedure of drug design. 
• End of chapter. 
Chapter 3 
Interactive Drug Discovery and 
Design • Overview 
Summary 
This section gives an overview to the algorithms inte-
gmted by ID3 framework. The framework guides the 
drug development in three steps: analysis, design and 
interaction. 
In this research, we focus on f inding a targeted drug which 
is more effective against cancer. The drug can also be designed 
48 
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for v i ra l protein to suppress their functions. We have designed 
an integrated framework to aid the user to identi fy drug tar-
gets. The user can then design drug candidates for the targets 
automatical ly or interactively using the framework. The gener-
ated drug candidates are visualised and the user can inspect the 
qual i ty of the solutions, supported by related information. We 
have integrated several algorithms to provide an easy way to use 
the drug design platform. We have also performed the following 
improvements. 
• A n algor i thm for protein function prediction is developed 
using a novel data representation heterogeneous vector. 
• A n improved drug design algorithm, SmartGrow, is de-
veloped using physico-chemical properties to enhance drug 
candidates' affinities. 
• A n interface using v i r tua l reality is produced to provide a 
p lat form for user verification and interaction. 
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The overall drug design framework is given in figure 3.1 
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Figure 3.1: Flow of IDS framework 
A t the top of the figure 3.1, i t shows the process of matching 
a similar structure of protein. Bubble 1 indicates the protein 
sequence we are studying. Bubble 2 shows clusters of protein 
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created by our a lgor i thm using novel heterogeneous vector. This 
step is used to discover the appropriate protein structure, also 
under bubble 2, as the drug target. Next is bubble 3, we abstract 
the i l lustrat ion of a drug target w i t h a b inding pocket. A drug 
candidate is placed in the binding pocket to calculate the affinity. 
The drug candidate can be evolved to create new candidates 
by adding fragments, as shown near bubble 4. This process 
repeats un t i l the drug candidates are too large or the populat ion 
converges. I t means the algor i thm loops between bubble 3 and 
bubble 4 un t i l the drug candidates are good enough. A t the 
bo t tom of the figure labelled 5，it shows an interface displaying 
the interact ion between the drug candidate and its target. We 
w i l l explain in more details in the fol lowing sections. 
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3.1 Protein prediction using secondary struo 
ture analysis 
The first step in designing a drug candidate for a disease is 
to identify a suitable target. The design process requires the 
structure of the protein target which can be found in the Pro-
tein Data Bank (PDB). PDB also contains information on the 
function of a protein which is essential for analysing whether a 
protein is a suitable drug target. The entries in P D B are of high 
quali ty because all entries are experimentally verified. However, 
the cost to resolve the structure of a protein using laboratory 
experiments such as X-ray crystallography is high. I n deciding a 
protein as a drug target, i t is necessary to know the funct ion and 
obtain its structure. Many protein function prediction methods 
require the use of protein structure to support their prediction. 
These methods are not useful when the structure of the protein 
studied is not resolved. However, only a relatively small port ion 
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of proteins has the resolved 3D structure in PDB. When a pro-
tein under study does not have a corresponding structure file, i t 
is necessary to find a similar structure to infer its properties to 
see i f i t is a suitable drug target. 
I n order to predict the function of a protein wi thout the struc-
ture, we have developed a compact secondary structure repre-
sentation called heterogeneous vector. Secondary structure can 
be predicted from protein sequence w i t h very high accuracy, 
which allows the heterogeneous vector to represent most pro-
tein sequences. This vector can be used in clustering to discover 
similar protein structures. When the algor i thm is applied to 
classification methods, i t can predict the funct ion of a protein 
provided w i t h t ra in ing data. The algori thm considers the sec-
ondary structure of a protein and incorporates the relative posi-
tions to generate a vector for comparison. The measurement is 
based on entropy to find the set of secondary structures and po-
sitions which can best describe protein similarities. Proteins are 
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labelled precisely by heterogeneous vector using groups of sec-
ondary structures. The similarity between the groups are mea-
sured using Eucledian distance and domain knowledge. When 
both groups of secondary structures are too distinct, a penalty 
factor is given instead. To calculate the similar i ty between two 
proteins, the groups of secondary structures are compared pair-
wise and their min imum distances are recorded. The similari ty 
between two proteins is a weighted sum of min imum distances 
on the groups of proteins. In benchmarking the effectiveness of 
the vector, this approach is applied on a clustering problem and 
a classification problem. The dataset is extracted from PDB 
and the protein functions are ground t r u t h for both problems. 
In performing clustering, the resulting quali ty is 2 times bet-
ter than state-of-the-art methods. When the vector is used for 
a 2-class classification, our algori thm performs 40% better in 
F-measure than similar approaches. 
CHAPTER 3. OVERVIEW 5 5 
3.2 Knowledge-driven ligand design 
Targeted therapy is a versatile way in curing diseases and cancers 
by delivering the medicines directly to the location needed and 
interact only w i t h the desired target, reducing adverse effect. A 
specific drug needs to be designed for each target. The cost for 
targeted therapy is high especially the process in discovering the 
suitable drug candidate can be slow. Computat ional drug design 
methods are favoured because of its efficiency. Our algorithm, 
SmartGrow, is designed part icular ly for this purpose. 
Given a protein target, our design process creates drug candi-
dates specifically for the target. SmartGrow employs fragment-
based strategy which appends fragments to drug candidates to 
increase their aff inity on the target. Evolut ionary algori thm is 
incorporated to generate mult iple configurations of drug can-
didates. The algori thm is run iteratively which improves the 
qual i ty of drug candidates each generation. The evaluation of 
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the drug candidates is performed by docking them to the target 
and ranked according to the free energy calculated. In the design 
process, the drug candidates str ict ly follow geometric constraints 
that the resulting shape is assumed valid. The drug candidates 
also pass through a filter on chemical properties which check if 
the candidates are water soluble. 
There are some novel enhancements incorporated into Smart-
Grow to achieve better results. First, two new operators are in-
troduced to control the weight of the drug candidates, as larger 
drug is less likely to be absorbed. Second, the average molecular 
weight of the drug candidates in each i terat ion is calculated to 
estimate the weight in the next generation. This measure can 
prevent the drug candidates being too heavy and in some cases 
reduce the weight of the drug candidate. Comparing Smart-
Grow to the state-of-the-art algori thm which also evaluates the 
candidates using a docking program, our algori thm creates an 
average of 10% higher aff inity drug candidates. I n addit ion, our 
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method covers a more diverse set of candidates w i t h up to 40% 
faster execution. The resulting set of drug candidates are in 
standard P D B file format which allows further verification. 
3.3 Interactive interface in virtual reality 
Visualisation plays an important role in understanding the func-
t ion of proteins and identi fying binding sites. In the last step of 
the framework, we develop an interface to visualise the proteins 
for two purposes. One purpose is to allow verif ication of the 
interaction between the drug candidates and their targets. The 
interface is modelled using v i r tua l reality which gives users the 
perception of depth, creating better sense of positions w i th in 
the 3D proteins. Support ing information to the interaction such 
as bonding and distance is also presented to aid user's decision. 
Through viewing the proteins, users can choose from an array of 
representations. When a protein is displayed in its atomic con-
figuration, the interface shows a detailed interaction between 
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the drug candidate and the protein. Different types of atoms 
are coded in their own colour for easy identification. The user 
can also choose to display a protein in its secondary structure. 
In this mode, the shape and local segments of the protein is 
presented. To identify possible binding sites of the protein, the 
surface mode should be selected. 
Another purpose of the interface is to act as a p lat form for 
interaction test. In order to use docking program or drug de-
sign program, parameters including coordinates information are 
inputted by the user. I t is not intui t ive to operate on coordi-
nates data wi thout visualising the protein. Wi thou t reference, 
the coordinates of a protein can be anything. Using the inter-
face, users can drag a drug candidate to the posit ion which they 
see fit. The users can also restrict the region to search such that 
the design algori thm can execute faster. The coordinates are 
calculated automatical ly by the interface. 
The V R interface is also integrated into our drug design or lig-
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and design algori thm - SmartGrow. I t allows human intelligence 
to be incorporated as part of the evaluation on drug candidates. 
Compared w i t h an automatic drug design algorithm, the inter-
active variant has an average of 20% better affinity. When the 
user confined the region to search for the binding site, the inter-
active approach saves 60% execution t ime compare to searching 
wi thout bounds. Moreover, the interactive approach can solve 
the issue of mult iple binding sites as the user can select a par-
t icular binding site for testing. 
• End of chapter. 
Chapter 4 
Protein Function Prediction 
using Heterogeneous Vector 
Summary 
A novel heterogeneous vector for protein similar i ty anal-
ysis using sequence and impl ici t structural information 
is discussed. I t showed 2 times better clustering quali ty 
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4.1 Introduction 
4.1.1 Motivation 
Discovering the functions of proteins is essential in understand-
ing their roles and effects in an organism. Current approaches 
include mult ip le sequence alignment and structure alignment to 
identi fy the domains of a protein[41, 42]. However, the capabil-
i ty of mult ip le sequence alignment w i th respect to the functions 
of proteins is being challenged [43]. Other sequence based meth-
ods, even using pat tern profil ing, are not performing very well. 
Many algorithms such as structure alignment such as TM-a l ign 
and CATH[22, 44] utilise sequence alignment as the in i t ia l pro-
cedure while they aim to discover the functional properties of 
protein. There are statistical analysis in comparing the proteins 
which require explicit structure, experimentally resolved coor-
dinates, of the proteins [45, 46]. Many previous work use their 
own interpretat ion in protein functions. C A T H uses superfami-
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lies to describe the protein function while TM-a l ign fold similar-
ity. I t makes the results of different protein funct ion prediction 
algorithms incompatible. Thus, these result cannot be used in 
algorithms which analyse standardised protein funct ion defini-
t ion. Whi le using experimentally resolved structure can greatly 
enhance the performance, i t may not perform well in de novo 
structure. As the number of resolved structure is few relative to 
the number of protein sequences, structure-based methods can 
only be applied to l imited scenarios. 
4.1.2 Objective 
Given a protein sequence made up by 20 types of amino acids, 
a protein function predictor returns the most probable function 
of the protein. A protein sequence is represented by a character 
str ing and each character represents an amino acid. The defini-
t ion of biological function in this work refers to the classification 
given in a P D B [14] file that describes the protein. 
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4.1.3 Overview 
In this work, we propose an alternative method in measuring 
difference of proteins based on their structural properties. The 
proposed algor i thm uses the secondary structures and their rel-
ative positions on a protein. The secondary structures of the 
protein are computed using the DSSP [47] which is known to 
have high accuracy in assigning the structure. The proposed 
algor i thm does not consider explicit structural information, in-
teraction networks and ontology thus does not require many re-
solved structure and can be applied to most protein sequences. 
I t can be adopted in consensus approach to further enhance the 
capabil i ty of current protein function predictors. The algori thm 
is designed to be flexible to incorporate informat ion beyond pro-
tein sequence such as domain and structure. 
The secondary structures is represented using a str ing a and 
their positions relative to the protein sequence as numbers N. 
Inspired by the representation of spatial databases [48, 49], we 
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propose a heterogeneous vector which measures the distance be-
tween proteins incorporating the structural information. Pre-
serving both numerical (positions) and non-numerical (secondary 
structure) data, we introduce an architecture called feature cell 
c to represent the feature of proteins. A feature cell can be re-
garded as a container to hold a combination of numerical and 
non-numerical data. The attr ibutes are grouped in a tree and 
formed a feature cell. The features of data points used in this 
work are experimentally verified and annotated in major biolog-
ical databases. 
Apar t f rom feature cells, we also propose a heterogeneous 
vector F , an architecture in organising feature cells. For each 
protein, a heterogeneous vector is formed to represent i t . A 
heterogeneous vector contains mult iple feature cells to represent 
distinct features of the data. The heterogeneous vector form a 
hierarchical architecture to organise the feature cells depending 
on the importance of them. The heterogeneous framework is de-
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signed to tackle problems where the data points contain mult iple 
features. The framework is especially efficient in handling data 
w i t h uncertainty like range and approximate matching. Under 
this representation, the detail is presented by a hierarchy of fea-
ture cells. 
We provide an extensive theoretical study on the heteroge-
neous framework to just i fy the approach. The proposed frame-
work acts as a bridging layer between existing simi lar i ty mea-
sure and data mining techniques. Through testing on the real 
datasets, the heterogeneous framework is found to be scalable 
and has a higher performance in terms of clustering qual i ty and 
predict ion capability. 
The remaining of the paper is organised as follows. The 
framework of producing heterogeneous vectors and measuring 
similar i ty on them is introduced in Section 4.2. Section 4.3 
describes data preparation and experimental methods. Experi-
mental results are in section 4.4. Discussion is given in Section 
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4.5 on l imitat ions and improvements. Section 4.6 is the conclu-
sion of this paper. 
4.2 Methods and Design 
In this work, we present a heterogeneous vector to integrate the 
feature of secondary structure into its protein sequence. Based 
on the heterogeneous vector, we calculate the simi lar i ty scores 
among proteins which are used to perform clustering and classi-
fication. We first introduce the concept of feature cell and het-
erogeneous vector. Each protein in the dataset is represented by 
a heterogeneous vector which is a collection of feature cells on 
protein sequence and its secondary structure. Through entropic 
analysis, a weight is assigned to every feature cell as feature se-
lection. Then we introduce the similar i ty among heterogeneous 
vectors which is a normalised distance of all the feature cells. 
Before we go into the details of the heterogeneous vector, we 
present an example on the structure of heterogeneous vector. 
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Start Position End Position 
\ /• Feature cell 
_ _ X ,广 / \ 
4 Helix 12 15 Helix 18 18 Turn 2 3 - 2 5 Helix 27 ——30 Strand 39 
Secondary Structure Type Heterogeneous Vector 
Figure 4.1: An example of the structure of a heterogeneous vector 
I n figure 4.1, we have i l lustrated an example of the structure 
of a heterogeneous vector which compactly represents a protein 
using the secondary structures and their positions relative to 
the protein sequence. We design the heterogeneous vector to 
compare posit ional and structural information together so as 
to achieve better performance. There are 3 types of secondary 
structures recorded in our heterogeneous vector, namely, helix, 
strand and turn. 
This heterogeneous vector consists of 5 feature cells. In the 
first feature cell on the left, i t is labelled helix and paired w i th 
two numbers. The number left of the label is the start ing po-
sit ion of the stated secondary structure, relative to the protein 
sequence. The number right of the label is the relative ending 
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position. Hence, we know that from the 4th amino acid to the 
Y 她 amino acid of the protein form a helix. The second feature 
cell also represents a helix. As the ending posit ion of the first 
cell is not the same as the start ing position of the second cell, 
there are considered as two separated helices and represented 
by two cells. In addition, different types of secondary structures 
are represented using mult iple feature cells, even they are ad-
jacent to each other. The straight lines in the heterogeneous 
vector represent the rest of amino acids in the protein which 
do not form any secondary structure. The technical details of 
the feature cells and heterogeneous vector are explained in the 
following sections. 
4.2.1 Feature Cell 
A feature cell c contains selected features of a protein Si in the 
dataset S(N, a), where N corresponds to the length of the pro-
tein sequence and relative positions of secondary structures; a is 
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a representation of the secondary structure. A protein consists 
of several important features such as motifs and a number of fea-
ture cells. To suit the architecture w i t h protein representation, 
a feature cell is defined as a 2-tuple 
C 二 (…iV2), 
where a denote the secondary structure or its mot i f and posi-
tions pair N^ are the start ing and ending positions of the cor-
responding secondary structure. The positions pair is used to 
hierarchicalise the feature cells. 
A feature cell is defined to be discriminative when i t is not 
encapsulated by another feature cell of the same protein. A 
discriminative feature cell is an important feature of the protein 
which contributes the most in calculating the distance. Consider 
a protein Si has n feature cells {c i , C2,. . . , c^}. A feature cell 
Ci = {cFi, [xii,Xi2]) is discriminative over Cj = (aj, [ x j i , X j 2 ] ) when 
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Cj is completely covered by a given 
{q〕Cj ： {Xii < X]i) A {Xi2 > Xj2)}. 
For example, a protein contains several independent alpha he-
lices and beta strands. Some of the helices together have formed 
a mot i f helix-loop-helix. In the framework, there are feature 
cells describing the motif, alpha helices and beta strands. The 
feature cell which represent a alpha helix of the mot i f is not dis-
criminative because i t is superseded by a larger feature cell that 
describes the motif. 
In the following example, we have five feature cells span-
ning a two dimensions to i l lustrate hierarchy of feature cells. 
In figure 4.2 (left), feature cell E has no overlapping neighbour 
which is discriminative. Feature cell D overlaps w i th feature cell 
A but i t is not completely encapsulated by other feature cells, 
making i t discriminative. For other feature cells which are not 
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B 
J^ LAJ b � 
A ——J C 
ID A L _ J 
Figure 4.2: An example on discriminative feature cells and their children 
discriminative, i t is necessary to assign them to a parent. A 
non-discriminative cell is assigned to the smallest cell that en-
capsulates i t . Feature cell B is a child of feature cell A since A 
completely covers B. Consider feature cell C, i t overlaps both 
feature cells A and B. However, B is sufficient to encapsulate C 
and is smaller than A. Feature cell C is assigned as a child to 
B instead of A. In figure 4.2 (r ight), there is another example 
on three feature cells. Both B and C are children to A because 
neither B nor C can completely encapsulate each other. 
4.2.2 Heterogeneous Vector 
A heterogeneous vector Pi of size n is a collection of non-redundant 
feature cells {c i , C2,. . . , c ” } which describe a protein Si. Here is 
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an example i l lustrat ing a data point in the set S、N\ a). I n fig-
"moti f a ' I [1,1 o f 
alpha helix [2,5] [ - - - j beta strand [6,10] 
Figure 4.3: A conceptual visualisation on heterogeneous vector. Solid line 
indicates different levels and dotted line indicates same level 
l ire 4.3，a heterogeneous vector on a 'mot i f A , of a protein is 
i l lustrated. The numbers in a feature cell describe the start ing 
posit ion and ending posit ion of the related entity, which is a 
secondary structure or moti f . The mot i f contains several com-
ponents and each of them is presented in a feature cell. I n this 
example， ‘motif A，is composed of two elements, a alpha helix 
and a beta strand. Bo th the alpha helix and the beta strand 
are children to the 'mot i f A ’ and they are on the small level of 
importance, denoted by the dashed line. Other heterogeneous 
vectors are of similar architecture and the distance is calculated 
by comparing the feature cells of the same level. 
In a heterogeneous vector, the feature cells can have no child, 
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a single child or mult ip le children. Hence, a heterogeneous vec-
tor is a collection of trees and the root node are discriminative. 
When measuring simi lar i ty among the heterogeneous vectors, 
the discriminative feature cells have fu l l influence while subse-
quent feature cells (children) have reduced impact based on the 
depth in the tree. 
6 Helix 1 3 - 1 4 Helix 1 8 - 1 9 Turn 23 30 Strand 39 
。I丄」—，I。 
4 Helix 1 2 — — j i s l Helix l i s l i s l Turn | 2 3 l - | 2 5 | H e l i x | 2 7 p ~ Q S t r a n d S —— 
\ _ | 1 1 I I 
。 . '--(- ••—I 。 
15| Defined Pattern 27 
Figure 4.4: An example on comparing two heterogeneous vectors 
I n figure 4.4, we have i l lustrated a comparison example be-
/ 
tween 2 heterogeneous vectors. The first vector contains 4 fea-
ture cells ci = ([6,13]，H), ([14，18]，H), ([19,23], T ) , a = ([30，39], S) 
and the second vector contains 5 feature cells C2 = ([4,12], H), ([15,18]，H), ([18,: 
In the second vector, several feature cells together form the pat-
tern hel ix-turn-hel ix p = ([15，27]，TiTi/) which is predefined 
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in our comparison model. We form a new discriminative fea-
ture cell spanning the 15th to 27th amino acids of the protein 
to promote the effect of this pattern in the comparison. The 
3 feature cells in the defined pattern have reduced effect when 
calculating the similari ty between the 2 heterogeneous vectors. 
In this example, thick lines mark every feature cell in the first 
heterogeneous vector to the closest feature cell in the second 
heterogeneous vector. To find out the closest feature cell of ci, 
i t is compared w i th all the feature cells from C2 to Cj. The closest 
pair is (ci,c2) and a thick line is drawn to indicate the pair. The 
similari ty between the heterogeneous vector is the normalised 
sum of all the distances from feature cells. In summing the 
distance, a solid thick line means ful l weighting in calculating 
the distance between 2 feature cells. A dotted th ink line means 
reduced weighting. The details in calculating the similar i ty be-
tween feature cells and heterogeneous vectors are explained in 
the following sections. 
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4.2.3 Feature Cell Similarity 
A feature cell contains two different data types, relative positions 
and a structural type a. I n order to find the s imi lar i ty among 
feature cells, we calculate the simi lar i ty on the positions pair 
dis{N^,Nf) and the structural types dis[cri,aj) independently, 
where q = (ai, N^) and cj = (aj, Nf) are two feature cells. The 
distance between two positions pairs is given by the Eucledian 
distance mul t ip l ied by the Jaccard distance 
"Ar2 ；vr2、’ \NiUm - TV2 n Nf 
、 J(Nf, m) = ！ L. 
V “ ] ) Nf U N^ . 
^ J 
The distance among structural types is binary that gives 1 i f 
bo th structural types match and 0 i f they are not matched. 
Using the simi lar i ty calculated, weights are applied to each dis-
tance, forming a combined simi lar i ty score which represents the 
distance between two feature cells. The fields in a feature cell are 
not equally important such that an adaptive weighting scheme 
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is adopted. Entropy of the data type is applied as a weight to re-
fleet the importance of a feature [50]. A field is more informative 
when its entropy is high which is more capable in distinguish-
ing the difference among proteins. Al though entropy requires a 
distr ibution, i t is feasible to estimate the entropy of the protein 
set. 
Consider a dataset of secondary structures on proteins 
w i th a f inite number of elements m. A heterogeneous vector P\ 
is constructed for every protein Si in the dataset S. We denote 
the average size of the heterogeneous vectors be n肌^ The tota l 
number of feature cells of the dataset S is n肌^m. Al though the 
relative positions field is in the support R ^ l imi ted representa-
tions are used because the length of a protein chain is finite. We 
consider the relative positions field described by the set of posi-
tions pairs D { N ^ ) = {a , , a? , . . . , a〜饥 | a, G R ” which is f inite 
and discreet. Since a secondary structure can exist in the same 
position across proteins, there are mult iple occurrences of pairs 
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in the set and we define the number of occurrence of the 
positions pair ki be freq(ai). Af ter removing the duplications in 
the set D〈N、, a non-redundant set is constructed and 
the number of elements in the set is denoted as \b \ < riavgm. 
From the obtained frequencies of the set a probabi l i ty 
咖 ) = f r ^ 
is computed and assigned to the positions pair which is used to 
estimate the distr ibut ion. Then the entropy of the numerical 
field is given by 
丨力I 
i=l 
Nevertheless, the distr ibut ion of the positions pair is too diverse 
which leads to a uniform distr ibut ion in our dataset. The distri-
but ion of the positions pair is thus calculated w i t h bin sampling. 
A b in contains a number of positions pair and the entropy is es-
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t imated using the bins. 
Similarly, we apply the same method on the structural type 
field to estimate the entropy. The structural type field is discreet 
in the first hand so we can form a non-redundant set D{a) w i th 
frequency freq{a) by retrieving all structural types a in the 
dataset S. The estimated probabil i ty of f inding cji in the set S 
is 
咖 ) 二 ： ^ ， 
where \D\ is the number of structural types in the set D{a). 
The entropy is denoted by 
I力I 
H 剛 ) = - j y w h g p ⑷. 
i=l 
From the similarities and entropies of all features in the fea-
ture cells, the similari ty for the feature cells is computed by a 
weighted combination. The similari ty between two feature cells 
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Ci, Cj is defined as 
dis{NlNf)H{D{N^)) 
freq{ai) + freq{aj) 
+ dis(ai,aj)H[D(a)) 
freq{(Ji) + freq[(jj)' • 
The first te rm is the combined distance of the positions pairs and 
the structural types; The latter terms represent their weighted 
entropies. Lower weighted entropy is assigned to frequently 
observed element due to the lower abi l i ty in distinguishing a 
feature cell f rom another. The distance of the feature cells is 
non-negative across any combinations of data and a value of 0 
indicates identity. 
4.2.4 Heterogeneous Vector Similarity 
The similar i ty between two heterogeneous vectors d i s {F i ,F j ) 
represents the distance between two proteins Si, s j in the dataset 
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I t is computed by considering the only the discriminative 
feature cells of the vector Fi against their closest counterparts 
in the other vector F j . Since a discriminative feature cell can 
contain subsequent feature cells, their similarit ies are also con-
sidered albeit reduced effect. When comparing a feature cell 
w i t h children to a feature cell w i thout children, a penalty factor 
is imposed. The penalty factor e is given as 
,—H{D(N^))H{D(a)) 
Tii + rij , r J 
where Ui^Uj are the number of discriminative feature cells that 
contain children in the heterogeneous vectors 艮 F j respectively. 
The penalty factor is then normalised to the sum of feature cells 
w i t h children in bo th vectors. 
We minimise the distance of two discriminative feature cells 
by choosing the closest pair of the encapsulated feature cells. 
Consider we have two feature cells cf, c，，their children at height 
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A: + 1 formed two children sets Cf, Cj. We find the elements in 
Cf，Cj which gives the minimum distance denoted as m i n ( C f , Cj). 
The min imum distance is given by 
f 
0, = Cj^  二 0 
1 e, C f = 0 ① C t = 0 
茨 (4.3) 
c f + i 々 i ) + 
, otherwise 
m i n ( C f + i , C广 1) 、 
where feature cells G Cf ’ c f+ i G Cj are chosen to give 
the min imum distance in accordance w i th the equation (4.1). 
The children sets Cf+i，Cj"+i contains the children of feature 
cells。》+1,(：广1 respectively. Determining the min imum distance 
requires distance calculations among all the elements in Cf and 
Cf . 
In algorithm 1，the steps to calculate the distance between 
two feature cells are detailed. The index k indicates the level of 
the children we are considering in a feature cell. When A; = 1, 
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Algorithm 1 Finding minimum distance mm(Cf, C^) 
1: if Cf and C � h a v e no element then 
2： return 0 
3： end if 
4: if either Cf or C � h a s no element then 
5： return penalty factor e 
6： end if 
7: min<~ sim(c，,c，+i) 
8: make variables (q , CJ) 
9: for each element G Cf do 
10: for each element G C^ do 
11: dist — 
12: if dist < min then 
13： min [ dist 
15: end if 
16： end for 
17： end for 
18: obtain children set C，+i from ( q , CJ) 
19: return ^min + min{C^+\ Cj^ +i) 
i t is the highest level such that the discriminative feature cells 
considered. A penalty factor wi l l only be given when the total 
height of the two discriminative cells are different. When both 
sets are not empty, we enumerate all possible combinations in 
the set to determine the closest distance. 
We consider a heterogeneous vector F has I the number of 
discriminative feature cells c^  which is regarded as the length 
of the vector. The distance between two heterogeneous vector 
. CHAPTER 4. PROTEIN FUNCTION PREDICTION 83 
Fi, F j is defined by 
1 [ i 
d i s ( f i , F j ) = sim{cl c j ) + min{Cl Cj), (4.4) 
几i 
where c] is chosen to give the min imum distance against c-, k 
is the number of discriminative feature cells in Fi and m is the 
number of feature cells in Fi. In other words, for each discrimi-
native feature cell in Fi, we find the most similar discriminative 
feature cell in Fj. The distance between heterogeneous vectors 
is a weighted sum of simi lar i ty measures of the closest discrimi-
native feature cell pairs. 
Algorithm 2 Calculating distance dis{Fi,Fj) 
total — 0 
for each element c} € Fi do 
min ^ sim(c”i, cf+i) 
for each element c] G Fj do 
dist [ sim(c}, c]) + min(C}, Cj) 
if dist < min then 
min •<— dist 
end if 
end for 
total = total + min 
end for 
return total 
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Algor i thm 2 illustrates the procedure in determining the het-
erogeneous vector distance. By f ixing a discriminative feature 
cell in the ith vector, all discriminative feature cells in the jth 
vector are tested, and each pair are computed to give a feature 
cell distance along w i th their children. The min imum combined 
distance is recorded for the feature cell in the ith vector. Since 
the size of two vector may not be equal, commutative property 
may not hold. Inherited from the distance of the feature cells, 
the similar i ty among the heterogeneous vectors is non-negative 
and ident i ty between two vectors results in the simi lar i ty to be 
0. I n finding the similarity, all the discriminative feature cells 
in Fi are tested once and the rest of the feature cells are used 
in obtaining a min imum distance using the criteria described in 
algori thm 1. 
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4.3 Experiments 
4.3.1 Data Preparation 
For the scalability test, a real dataset of 6388 transcript ion fac-
tors is collected. The proteins in the dataset are represented us-
ing a sequence, Pfam index w i th positions. Pfam is a database 
on protein families which contains annotations of functional re-
gion, known as domain, for proteins [17]. The proteins found in 
nature are often a combination of domains such that the identi-
f ication of domains provide insights to the funct ion of proteins. 
Each protein in the dataset contains at least 1 Pfam index on 
its domains and positions w i th respect to the protein sequence. 
A protein sequence can be regarded as a str ing a of length 1 
using a f inite alphabet set S where the size of the alphabet set 
is |S| = 20. The average length of all proteins lavg in the dataset 
is 404 residues. As the Pfam index cannot be compared directly, 
i t is only used to evaluate the efficiency of the algorithm. The 
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positions of a Pfam index are represented in a pair 
In producing the dataset for clustering and classifications 
studies, we obtained a set of proteins of different functions which 
is not the set used in the scalability set. The functional class 
were extracted from the PDB [14] which are experimentally ver-
ified. I n l ight of mult iple experiments on the same protein, du-
plication removal was performed by associating the P D B entries 
w i th the Uniprot [51]. To ensure high quali ty result, we con-
sidered experiments using X-ray diffraction only. I f a protein 
chain is associated w i th mult iple entries in PDB, we selected 
the entry of best resolution of the protein chain. In order to 
verify whether the association is correct, the sequence stated 
in the Uniprot is aligned w i th the corresponding chain in the 
PDB. Associations were rejected when the shorter chain is less 
than 80% length of the longer chain. Pairwise alignment was 
performed on the remaining chains using local alignment w i th 
80% similar i ty threshold. I t resulted in 8004 protein chains that 
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met the criteria. From the curated protein chains, we produced 
datasets for classification of functional simi lar i ty and dissimi-
larity. One set FunS contains 520 ' transcript ion' proteins and 
171 'dna binding' proteins which shares high similar i ty in bind-
ing D N A . The other set FunD contains 1612 ‘transferase, and 
1818 'hydrolase' which performs different chemical action. In 
the dataset FunD, 20% of the proteins are of mult iple functions 
where one of the functions is transferase or hydrolase. 
4.3.2 Experimental Methods 
Scalability 
We created a heterogeneous vector for each protein based on its 
Pfam index and positions wi thout using the protein sequences. 
The heterogeneous vector for a protein i is given as 
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where m is the number of proteins in our dataset. The distance 
among positions pair is an adjusted Euclidean distance described 
in the method section. In calculating the distance between Pfam 
indices, its description is considered instead. The description of 
the indices are compared using edit distance approach. For a 
l imited amount of shift ing of a str ing against another string, 
the edit distance is calculated for each character shifted. The 
strings shifted do not necessarily overlap completely where some 
characters always incur an edit distance since i t has no counter-
part. The best edit distance obtained among all calculation 
using shift technique indicates a str ing is best-aligned against 
another string. The whole sentence is shifted together using 
a l imi t of 80% of the shorter sentence such that at least 80% 
of the shorter sentence is overlapped w i t h the longer sentence. 
The final similar i ty is normalised so that ident i ty between the 
domains is 1. 
As a heterogeneous vector can contain different number of 
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feature cells, we tested on the t ime complexity against the num-
ber of feature cells. From the dataset, we selected heterogeneous 
vectors which are solely composed of discriminative feature cells. 
We further separated the selected vectors based on the number 
of feature cells. Another set of heterogeneous vector was pro-
duced w i t h at least one of the feature cells contain a child. This 
set was then divided based on the number of discriminative fea-
ture cells they contain. The divided sets contain at least 100 
different samples. There are six sets produced by accounting 
the discriminative feature cell only and five sets when there is 
at least one discriminative cell that contains children. For each 
set, we performed a non-redundant comparison among all het-
erogeneous vectors w i th in the set. The execution t ime of each 
set is normalised to lOK calculations. 
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Clustering 
We compared the clustering quality of these proteins using het-
erogeneous vectors and CD-HIT [52]. We have tested the clus-
tering algori thm in BLAST [15] but i t failed to produce mean-
ingful clusters for comparison. Since our algori thm is a sim-
i lar i ty measure, we implemented the same clustering strategy 
as CD-HIT , using representative sequences and a heuristic ap_ 
proadi. Using the selected set of proteins, we constructed the 
input sets for CD-H IT and heterogeneous vector respectively. 
The secondary structure data are extracted from the Uniprot 
over the P D B because the data in the Uniprot is more compre-
hensive. We formulated the secondary structure in fasta format 
for CD-HIT . Instead of a sequence of residues, the characters are 
replaced using the symbols of secondary structures. We consid-
ered three types of secondary structure, namely, helices, strands 
and turns. 
In forming the input data for CD-HIT , we first retrieved the 
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residue sequence of the protein chain. The residues were re-
placed by their secondary structure symbols if i t is a part of the 
secondary structure, or ‘」otherwise. The secondary structure 
symbols are '0' for the alpha helices, for the strands and 'T , 
for the turns. In forming the 1-level heterogeneous vector, each 
feature cell d id not contain any child. A feature cell includes 
the type of secondary structure, the start ing posit ion and the 
ending posit ion relative to a protein chain. I f mult ip le residues 
belonged to the same type of secondary structure, they were 
grouped into the same feature cell, recorded using the position 
of the start ing residue and the ending residue. 
We also tested the 2-level heterogeneous vector where there is 
a hierarchy of features. The secondary structure were grouped 
into tr i -mer w i th a maximum gap l imi t of 1% of the tota l chain 
length between the adjacent structures. There were only four 
types of tr i -mer considered which were helix-turn-helix, helix-
strand-helix, strand-turn-strand and strand-helix-strand. For 
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simplicity, different types of unmatched secondary structures 
had a distance of 1 and similar tri-mers, for example helix-turn-
helix and helix-strand-helix, had a distance of 0.5. 
To compare the clustering quali ty of CD-H IT and hetero-
geneous vector, we tested the parameters that both algorithm 
would result in a similar amount of clusters. We produced ap-
proximately 100 clusters using a 80% sequence similarity, a 60% 
length cutoff and local alignment w i th respect to the shorter 
seqeunce using CD-HIT . This set of parameters was chosen ac-
cording to the solution quali ty which produced much better re-
sult than the default parameters. For clustering of heteroge-
neous vector, we set a cutoff of 0.5 penalty factor, for the 1-level 
variant, and 1 penalty factor, for the 2-leveI variant, against 
the representative heterogeneous vector. The positions of a sec-
ondary structure was normalised to the length of the protein 
chain，such that the first residue of the chain has a posit ion of 
0 and the last residue of the chain has a posit ion of 1. The 
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entropy of the positions pair was estimated through sampling 
w i t h 10 bins. For example, i f there is a feature w i th in the first 
10% posit ion of the protein chain, the count in the first b in was 
incremented. I f a feature crossed mult iple bins, all the bins i t 
crossed wi l l have their counter incrementec. 
From the clusters produced, we evaluated the qual i ty w i th 
respect to the protein classification. We sampled the data set in 
different sizes to evaluate the behaviour of the algorithm. From 
the in i t ia l dataset, 4 smaller datasets were created by randomly 
sampling 20%, 40%, 60% and 80% number of protein chains from 
the original dataset. There was some issues that C D - H I T could 
not recognise all the sequences in the input files thus there would 
be less sequences clustered in the comparison. The experiments 
were performed on a machine w i th Core-i7 2.8GHz, 8GB R A M . 
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Classification 
We further analyse the potential of the algor i thm on classifying 
protein function. The definit ion of protein funct ion is ambigu-
ous or different among predict ion algorithms which a quanti-
tat ive comparison may not be possible. Some methods use the 
annotated domains or gene ontology to assess the rate of success 
of their algorithms. In our study, the proteins studied can con-
ta in mult ip le domains and annotated gene terms that the P D B 
classification is considered as the class label. Methods for p r o 
tein funct ion predict ion can be generally considered as sequence-
based and structure-based. Sequence-based methods operate on 
sequence alignment such as BLAST[53] and pat tern matching 
such as HHsearch[16]. Structure-based methods account a di-
verse set of features including fold similarity[19, 20，21], b inding 
pockets[23] and template modelling[22]. The algor i thm we have 
proposed lies somewhere in between that the s imi lar i ty is calcu-
lated using secondary structure wi thout alignment. 
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Based on the clustering method we have discussed, a ma-
chine learning technique similar to random forest [54] is applied 
to construct the classifier. In order to perform statist ical anal-
ysis on the prediction, classifications performed were on a 2-
class problem while the algori thm can be easily extended for 
multi-class ranking. Using the curated dataset from the previ-
ous experiments, two classes were extracted and converted into 
2-level heterogeneous vectors. Clustering was performed upon 
each class of protein independently, resulting in a number of 
clusters which can be used as classifiers. For a protein sequence 
to be tested, i t is converted into heterogeneous vector Ft and 
distance is calculated against all the representative vectors Fr 
in the clusters. The distance is compared w i t h the distance l imi t 
distmax of the clusters and is considered as a hi t i f i t is smaller 
than the distance l imi t dis{Ft,Fr) < distmax. A l l the clusters 
report hits or misses of the test vector and a threshold on the 
number of hits required is estimated. From the t ra in ing set for 
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clustering, a certain percentage of vectors are selected for vot-
ing among the same class of clusters. Only some clusters report 
hits and the number of hits for each vector is sorted in ascending 
order; a cutoff is taken to obtain a threshold on the number of 
hits required to classify a protein to the class. 
A l l experiments were performed using 10-fold cross-validation 
and the 2-level heterogeneous vector. For the dataset FunS, we 
used a cluster factor of 1.5 to suppress the number of clusters, 
resulting in an average of 15 clusters. 20% of the t ra in ing vectors 
are used to estimated the threshold w i t h a cutoff of 0.3. For the 
dataset FunD, a cluster factor of 0.4 was used and an average 
of 120 clusters were produced. The threshold is estimated upon 
30% of t ra in ing vectors w i th a cutoff of 0.2. 
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Figure 4.5: Execution time on different number of discriminative feature cells 
4.4 Results 
4.4.1 Scalability 
In figure 4.5, we plotted the execution t ime normalised to lOK 
comparison among the same type (wi th or wi thout children) 
against the size of heterogeneous vectors, 10 runs averaged. 
W i t h discriminative cells only, the increase in cost was mostly 
linear. A l though each discriminative feature cell needs to be 
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compared against all discriminative feature cells in another het-
erogeneous vector, i t appeared to be scalable in real situation. 
Considering the heterogeneous vector w i th children, the trend 
was more complicated. Calculating the vectors of a single dis-
criminative cell was more time-consuming than two discrimina-
tive cells. After investigating the dataset, we found out that the 
average number of feature cells in a vector is large. The number 
of children is 2.47 times more than the number of discriminative 
feature cells. Hence, in the set of single discriminative cell w i th 
children, every vector contains an average of 3.47 feature cells. 
Not all children cells are compared due to the penalty factor 
in the calculation which helps in achieve lower execution time. 
Therefore, we consider the first case as an outl ier and plotted 
the chart using the remaining cases. Consider the case that 
there are three discriminative feature cells. The execution t ime 
is almost equal between the heterogeneous vectors w i th or wi th-
out children cells. I t is observed that the algor i thm took more 
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Figure 4.6: The averaged execution time of 10 runs between CD-HIT and 
heterogeneous vector 
t ime to compute the distance among heterogeneous vectors w i th 
children. 
4.4.2 Cluster Quality 
I n figure 4.6, the averaged execution t ime of 10 runs was plot ted 
against the datasets of different sizes. The 1-level and 2-level 
variants of heterogeneous vector were denoted by hetero-1 and 
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Figure 4.7: Clustering quality on different quality threshold: heterol indi-
cates the simple heterogeneous vector, hetero-2 indicates the advanced het-
erogeneous vector 
hetero-2 respectively. The 1-level heterogeneous vector took al-
most twice the t ime to execute than the other algorithms due to 
the exhaustive behaviour in determining the distance between 
two data points. For 2-level heterogeneous vector, the execution 
t ime reduced by half to a level that its performance is compa-
rable w i t h CD-H IT . I n the 2-level variant, the number of dis-
cr iminat ive feature cells was fewer than the simple form since 
the cells form a hierarchy, while maintain ing the same amount 
of information. A l l a lgor i thm exhibited a linear behaviour in 
execution t ime according to the number of data points. 
In figure 4.7，we showed some results on the clustering qual-
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i t y of the algorithms. A qual i ty of 2 stands for an average of 
2 protein chains in one cluster sharing the same function, ob-
tained f rom the PDB. A n algori thm is considered better i f more 
similar elements together were clustered together. For a qual i ty 
of 2, the heterogeneous vector in the 2-level variant exhibited 
a similar t rend as CD-HIT . The 1-level heterogeneous vector 
leaded all the cases. When a stricter qual i ty requirement was 
applied, the cluster quali ty by the heterogeneous vector was up 
to 40% better than CD-HIT . When we require a cluster to have 
an average of 5 proteins of the same function, C D - H I T and the 
simple heterogeneous vector could barely produce any clusters 
that met the criterion. The 2-level heterogeneous vector, pro-
vided w i t h sufficient data points such that entropies could be 
estimated more accurately, performed up to twice better than 
the alignment-based approach. 
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Method Sensitivity Specificity F-measure 
HeteroVector(FunS)0.776 0.754 
HeteroVector(FunD) 0.806 0.530 0.637 
CHUGO - - 0.63 
b l a s t - - 0.54 
Table 4.1: Classification quality across different prediction methods. For 
reference only since different incompatible datasets are used 
4.4.3 Classification Quality 
One class in the dataset is considered true class and the other 
false class. True positive (TP) and true negative (TN) repre-
sents the correct classification of a class. False posit ive (FP) 
and false negative (FN) indicates the wrong classification of a 
class. The sensit ivity r, specificity p and F-measure are given 
by TP/{TP + FN\ TPI、TP + FP) and 2 (p ) ( r ) / ( p + r ) where 
F-measure is interpreted as the performance of the classifica-
t ion. I n table 4.1，the solution qual i ty among different meth-
ods is detailed using 10-fold cross-validation. Other methods 
evaluate over Gene Ontology which cannot direct ly compared 
w i t h our datasets. Our algor i thm performed well on the FunS 
dataset which is biased and more dif f icult to t ra in. For the 
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FunD dataset, the classes were more balanced but over 20% of 
the t ra in ing data are multi-class which makes the experiment 
more than a 2-class classification problem. The sequence un-
der test in the FunD dataset may not correspond to the correct 
class. Our algor i thm continued to produce comparable quali ty 
which is robust against noise. Comparing to the baseline methoc. 
B L A S T and similar method which uses Gene Ontology[55], our 
algor i thm has better performance. 
4.5 Discussion 
The proposed heterogeneous vector is designed to integrate sev-
eral features to improve distance calculation. I t does well when a 
protein contains many features such that the variety among het-
erogeneous vectors is more pronounced. The hierarchical design 
of grouping feature cells in a heterogeneous vector encourages 
detailed representation which does not incur too much penalty 
in performance. The vector representation is flexible in mod-
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elling a problem. In the experiments, we utilise data which are 
described by mult iple features, where each feature cell contains 
a hierarchy. Whi le tradit ional methods in dealing w i th many 
problems could arrive an acceptable solution, i t slowly becomes 
less effective as more information could be incorporated but they 
cannot be util ised in the tradi t ional way. From the experiments 
on protein functions, we showed an supplementary method to 
solve the protein grouping problem where the current method is 
being challenged. 
4.6 Conclusion 
This paper presents a heterogeneous framework on handling 
mult iple data types simultaneously. I t is suited for more com-
plicated problems where data points are represented in a de-
tai led way. Using existing similar i ty measurement on different 
data types, we combine the effect statistically based on entropy. 
The theoretical study on the framework is presented based on a 
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subset of usually applied data types. We gave examples on how 
current problem can be redefined w i l l proper usage of the frame-
work. Through testing on real dataset, the heterogeneous frame-
work showed favourable scalability over the number of feature 
cells. The framework is also able to represent a problem using 
informat ion that is diff icult to be util ised in current methods. 
Compared to current methods in clustering proteins according 
to their function, the heterogeneous framework produced more 
meaningful measurement and up to twice better cluster qual i ty 
than sequence alignment. I t has also performed well in protein 
funct ion prediction, even w i th noise injected. We envisage by 
incorporat ing other kinds of feature, the heterogeneous vector 
has a wider range of application. 
• End of chapter. 
Chapter 5 
Knowledge-Driven Drug Design 
Algorithm 
Summary 
We have developed a drug design algori thm using ge-
netic approach and evaluated by docking program which 
achieved 10% better free energy and acceptable molec-
ular weights w i th reduced execution t ime 
— 
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5.1 Introduction 
5.1.1 Motivation 
W i t h increasing cost in opt imising a new drug through exper-
iment, computat ional design method becomes more favourable 
and newer methods enable identif ications or synthesis of com-
pounds tha t could be potent drug candidates. Many techniques 
have been developed and physics-based approaches have achieved 
good accuracy. Physics-based approaches like thermodynamic 
integrat ion [33，34] here achieved accurate free-energy predic-
t ion at the expense of computat ional complexity. I n contrast, 
fragment-based approaches enable wider diversity and a lower 
computat ional cost. I n this paper, we w i l l introduce a knowledge-
driven fragment-based drug design framework called SmartGrow. 
Fragment-based growing strategies [3, 4], which create novel 
structures by adding interacting moieties to a fixed scaffold, are 
generally more popular than brute force v i r tua l screening due to 
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its lower computational expense and the higher degree of diver-
sity. Many of the algorithms produce de novo structures [35, 36, 
37, 10] and take into account of the structural information of the 
receptor [38]. Evolutionary algorithms (EAs) are also employed 
to produce larger diversity of structures [5, 6]. The fragment-
based approach has been recognised and contr ibuted to many 
FDA-approved drugs [2]. However, most of the fragment-based 
approaches do not account for the flexibility of the ligands re-
sult ing in inaccurate results in many situations. A recent sys-
tem, AutoGrow, addresses the issue by incorporating a docking 
algori thm into fragment growing techniques [39]. AutoGrow is 
one of the drug design algorithms which uses a growing strategy 
to bui ld upon an in i t ia l core scaffold; molecular fragments are 
added at random to this scaffold, thereby generating a popula-
t ion of novel compounds. The EA then evaluates the docking 
scores of each populat ion member, and the best candidates be-
come the in i t ia l populat ion of the subsequent generation. Nev-
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ertheless, the E A in AutoGrow is underuti l ised and could suffer 
f rom early convergence. Besides，there is no guarantee that the 
resultant compounds would carry drug-l ike properties, which 
enables them to funct ion in organisms. 
5.1.2 Objective 
Given a protein target, we aim at designing a drug to inter-
act and b ind to the target computational ly. A drug is most 
commonly an organic compound, also known as ligand, which 
activates or inhibi ts the funct ion of the protein target result ing 
in therapeutic benefits to the patient. The drug should be easily 
administered and have min imal side effects to patients. 
5.1.3 Overview 
Our proposed framework SmartGrow works interactively w i t h 
energy scoring functions [56, 57] and docking algor i thm [58 . 
Our a lgor i thm contains an advanced E A w i t h new operators, 
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allowing better coverage in the solution space and prevent pro-
ducing excessively large ligand; and we use a distr ibuted be-
haviour model [59] to address early convergence. For each gen-
eration, post-processing is also applied to ensure the major i ty of 
the produced ligands are val id and carry drug-like properties. 
In the computer-aided approach, the lead compounds against 
the protein target does not need to be synthesized in the wet lab-
oratory. I t avoids unnecessary side-product in producing a com-
pound and reduces experimental costs. Different f rom classic 
v i r tua l screening, the compounds being tested do not necessarily 
exist in the current drug database, which allows the oppor tun i ty 
of discovering new eligible compounds against a protein. 
The rest of this article is organised as follows. I n section 
5.2，SmartGrow w i l l be presented in detail. I n section 5.3, a 
comprehensive set of test data and their preparat ion w i l l be de-
scribed. In section 5.4，the result of SmartGrow w i l l be detailed 
and comparisons w i l l be made against other a lgor i thms。The 
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last two sections w i l l be discussions and conclusion respectively. 
5.2 Methods 
Since the solution space of possible compounds is extremely 
large and complex, EA is applied to discover the good candi-
dates in the solution space [60]. SmartGrow is bui l t on the EA 
using five operators. The five operators are as follows: 
• Selection to obtain high aff inity l igand based on evaluation 
score 
• Mutation to append fragment to in i t ia l l igand 
• Crossover to exchange fragments between two ligands 
• Merge to combine two small ligands into a larger one 
• Split to break a large ligand into two smaller ones 
EA mimics the biological process in nature where its pro-
cedure is divided into generations. Each generation contains a 
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number of individuals derived from the previous generation us-
ing some genetic operators. The selection operator picks out a 
number of best individuals, based on the evaluation function, 
to be carried over to the next generation. The mutat ion and 
crossover operators give variations to the individuals such that 
they would have a chance to improve their fitness. The mutat ion 
operator acts as the main growing operation in our framework 
which appends new fragments to an individual f rom the frag-
ment libraries. The crossover operator exchanges fragments be-
tween two randomly chosen individuals to create a new ligand. 
Thus，a potential solution would be evolved after a number of 
generations. Two addit ional novel operators, merge and split, 
are introduced to speed up the process and maintain diversity. 
The overall design is described in the following pseudo-code. 
The flow of our algori thm is controlled by a cohesion factor 
C(g、and a separation factor S{g) that promote diversity and 
force a convergence. Both factors are linearly proport ional to 
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Algor i thm 3 SmartGrow Design Flow 
1： Initialise population 
2: for Match stopping criteria do 
3： Evaluate (docking or scoring) 
4: Get elitist and calculate best parameters 
5: Mutate or Crossover ligands 
6： for each resulting ligand do 
7: if Far from best parameters then 
8： Split mutated ligand or 
9: Merge parents used for Crossover 
10： end if 
11： end for 
12： if Has drug-like properties then 
13： Assign to next population 
14： end if 
15： end for 
16： return High ranking ligands 
the current generation index against the to ta l number of gener-
ations. The factors are given by 
⑷ = 悬 ， S ⑷ = 1 一悬 （5.1) 
where g is the index of the current generation and G is the tota l 
number of generations. The two factors w i l l affect the choice of 
operators in each generation and wi l l be discussed in detail later 
in this section. 
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SmartGrow uses AutoDock Vina [58] as the evaluation func-
tion，and for flexibility, any docking or evaluation programs can 
be called in our design. SmartGrow can be controlled by ad-
just ing the parameters regarding the number of generations and 
other features. There are several important parameters to be 
set. The number of ligands (individuals) to be carried to the 
next generation, the number of mutated ligands and the number 
of children produced through crossover are indicated by Ns.Nm 
and Nc respectively. The actual figures could vary since the EA 
we implemented works on a variable populat ion P determined 
by 
P = + + [S{g){Nm + N,)]. (5.2) 
Different f rom tradi t ional fragment-based methods, there are 
mult iple principles to append the fragments to the in i t ia l scaffold 
in the algorithm. The rest of this section is divided into the 
following subsections: Fragment Joining, Genetic Operators and 
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Post-Processing. 
5.2.1 Fragment Joining 
Fragments refer to the bui lding blocks in the construction pro-
cess of drug candidates. A seed, the in i t ia l scaffold, is placed 
in a binding site of the protein target. Fragments are subse-
quently added one by one on the in i t ia l scaffold and the process 
is known as fragment joining. The jo in ing method forms the 
basis of the genetic operators of the algori thm to enhance the 
aff inity of drug candidates. Fragment jo in ing can be found in 
Mutat ion, Crossover, Merge and Split. The jo in ing method re-
places a random hydrogen atom on the l igand w i th a fragment. 
In most of the cases, the ligand and the fragment are joined to-
gether by dropping a hydrogen atom from each side and sharing 
the bond which is originally occupied by the hydrogen atoms 
respectively. In this scenario, the hydrogen atoms on the ligand 
and the fragment are randomly chosen. Our algori thm could 
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intell igently fix incomplete structures to achieve a more diverse 
search. The resulting compound is rotated to reflect its native 
conformation based on the information derived from empirical 
results and thermal dynamic properties. 
5.2.2 Genetic Operators 
Selection 
The selection operator is based on an external evaluation func-
t ion to calculate the score. Using the aff inity returned from the 
evaluation function, the individuals are ranked accordingly, w i th 
possible modif ication based on the number of atoms in a ligand 
when the small l igand mode is enabled. The adjustment is made 
inversely proport ional to the number of atoms in a ligand, which 
encourages smaller ligands which can be absorbed more readily 
61]. The aff inity from the evaluation funct ion w i l l be adjusted 
as follows. 
= (5.3) 
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where AG is the relative Gibbs Free Energy of the molecule 
complex, n is the number of atoms in a l igand and N is the 
max imum allowed number of atoms. The higher ranking ligands, 
indicated by lower adjusted aff inity score, w i l l be carried over to 
the next generation. 
Mutation 
The mutat ion operator modifies drug candidates in the genera-
t ion such that the ligands grow larger. A fragment is randomly 
selected in the fragment libraries for each l igand in the genera-
t ion. Only one fragment is appended to the selected posit ion of 
the l igand each t ime this operator is invoked. This operator is 
also used to create the in i t ia l populat ion from the in i t ia l scaf-
fold. For the rest of generations throughout the algorithm, i t w i l l 
choose a random ligand among the carried over individuals and 
append a fragment to i t . The joined fragment wi l l be considered 
as a part of the scaffold. I n the subsequent generations, a new 
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fragment could attach to the joined fragment in the previous 
generations. This operator also rotates the bonds of the scaffold 
such that the resultant compound is in its native conformation, 
where the distance among all atoms is maximised. 
Crossover 
The crossover operator mimicked the process of evolution where 
a new individual is produced from a pair of good parents. As 
each parent could contain a different set of fragments, the pro-
duced child would be significantly different by mix ing the sets of 
fragments, but l ikely maintains the qual i ty of its parents. The 
core scaffold, which is common in the parents, is retained and 
some fragments are exchanged in the child. The child w i l l first 
connect all the fragments from both parents so the child is able 
to access the fragments from both parents. When there are more 
than one connections on an atom, the chance of choosing any of 
the connections is the reciprocal of the number of connections. 
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Merge and Split 
Though the t radi t ional operators of E A could produce good lig-
ands, the populat ion w i l l quickly lose drug-like properties when 
they can only increase the size of the l igand indefinitely. On the 
other hand, sometimes we want to accelerate the growing of the 
ligands. In order to address these issues, we introduce a term 
MWb, which represents the expected molecular weight (operator 
control reference) for the next generation w i th the set of high 
ranking ligands. The term M W ^ is calculated by considering 
the weighted average of molecular weights from Ng number of 
ligands, which are carried ligands from the previous generation. 
The set of high ranking ligands are sorted in ascending order of 
aff inity that the ligand w i t h the lowest free energy is considered 
the best. The weight wj for the jth l igand among the carried 
ligands is given by 
[ N ^ , . 
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such that the influence of a ligand decreases exponential down 
the ranks. The expected molecular weight for the next gener-
ation, depending on the weighted average of molecular weights 
among carried ligands, is 
攝 + 悬 + 5。 （5.5) 
where MWj is the molecular weight of the jth l igand among the 
carried ligands. A constant terms is added iteratively in each 
generation in the equation to allow headroom for the l igand to 
grow. 
Merge: The merge operator migrates all fragments on one lig-
and to another ligands such that mult iple fragments are ap-
pended at the same time. Sometimes the child after the crossover 
operation could be too small compared to MWb as some frag-
ments are not retained in the process. In order to accelerate the 
growing process, we have introduced a merge operator. I f the 
CHAPTER 5. DRUG DESIGN 121 
parent is estimated as too small, the result ing chi ld after the 
crossover operation would l ikely be small. Given the probabil-
i ty variable c G [0,1)，the choice of using merge operator over 
crossover operator is controlled by the fol lowing equation: 
0m{2{MWb) — MWi - 罵 働 ) ( - 1 二 _ ) - 0 . 1 > c 
(5.6) 
where MWi, MWj are the molecular weights of the parents anc. 
C{g) is the cohesion factor of the current generation. A n upper 
bound for the molecular weight of 600 Da is observed in most 
of the exist ing drugs. The child would maximal ly contains all 
the fragments f rom the parents, rapidly increasing the weight in 
l ight of reaching the target size. 
Split: The split operator removes some of the fragments on a 
l igand, reducing the molecular weight of the l igand affected. I t 
is used to tackle the issue that the result ing ligands are too large 
to be drug candidates. Due to the characteristics of the l igand 
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growing strategy, the produced l igand increases in size mono-
tonical ly such that the opt ima could have been missed. Whi le 
the employment of E A reduces this probabi l i ty, i t does require 
a large populat ion size. Since i t is computat ional ly expensive 
to perform protein docking, we introduce a split operator which 
addresses the issue. I f a l igand is too large, based on M W ^ , the 
split operator w i l l be invoked. A reference l igand in the previous 
generation is randomly selected such tha t the por t ion common 
to the high qual i ty reference l igand could be retained. The rest 
of fragments that are not shared by the oversized chosen and the 
reference ligands are to be discarded or reused. We test the size 
of the l igand after the mutat ion is performed. To decide whether 
to split the mutated ligand, given a chance variable c G [0，1), is 
given as follows: 
0 . 0 3 3 ( C ⑷ + 0 . 1 ) ( _ 卯 厂 ” ( M W • 广 蕭 0 . 0 3 3 > c (5.7) 
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where Ni is the number of atom of the mutated l igand and S{g) 
is the separation factor of the current generation. The split 
operator w i l l be performed if equation 5.7 is satisfied. To max-
imise the effectiveness of this operator, we collect the discardec 
fragments and add them back to the l igand population. Hence, 
there would be two different but smaller ligands produced by the 
split operation. I t also carries an advantage that diversity conic, 
be maintained. Nevertheless, we would like to l im i t the com-
putat ional expense as every split operation would increase the 
populat ion which is undesirable. We impose a l imi t on the num-
ber of individuals in a generation P which varies as described 
in previous section. I f the number of ligands in the generation 
already exceeds P, there is a 50% chance that one of the two 
ligands produced by split operation is rejected. Therefore, at 
the later stage of the algorithm, less ligands wi l l be produced 
due to a smaller P which encourages convergence. 
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5.2.3 Post-Processing 
Although the solution space is a collection of graphs where the 
number of solutions is uncountable, the chemical and biologi-
cal properties could be taken into account to narrow down the 
searching space. There are several factors that we could con-
sider. For example, the electron orbi tal of an atom which de-
fines the maximum number of connections possible, Van der 
Waal's repulsion, Gibbs free energy and l ipophil icity. They are 
described briefly below. 
Electron Orbital 
To efficiently implement the concept on electron orbital, we pre-
define the maximum possible number of connections along w i th 
other useful information for common element types. I f a hydro-
gen atom in a structure is connected to two or more atoms, we 
can simply reject the structure. Al though i t is less common that 
a nitrogen atom is connected to four other atoms, i t is chemi-
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cally feasible so the l imi t for nitrogen is four such that we do 
not overkil l the population. 
Apar t f rom the configuration of a ligand, the conformation of 
ligands also largely depends on the orbi tal of atoms. In many or-
ganic compounds, there is an aromatic structure, especially the 
four basic bui ld ing blocks of D N A contains an aromatic ring. 
The aromatic structure is special in its shape, and all atoms 
which are part of the aromatic structure lie on the same plane. 
This k ind of structures is planar which greatly restricts the pos-
sible conformation of a compound. Since the exact calculation of 
orbi ta l would be computational ly expensive, i t is estimated in a 
rule-based principle. By looking at the number of connections, 
elements, bond lengths and the maximum number of possible 
connections, we can estimate whether an atom is connected by 
a part ia l unsaturated bond. For example, a carbon atom is con-
nected to three other atoms and the bond length is shorter than 
a usual single bond. We predict this carbon atom to be part of 
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an aromatic structure. When we are able to find a pair of these 
atoms, the fragments connected to the pair is rotated such that • 
the fragments lie on the same plane. 
Van der Waal's repulsion 
As each atom contains protons and electrons, the instantaneous 
positions of protons and electrons cause part ia l charge on the 
atoms. Thus the atom is not always neutral and wi l l repel other 
atom when they are too close. Atoms of different elements wi l l 
have different magnitude and distance of repulsion. To simplify 
the representation, we employ a universal cutoff of l . l s A f o r any 
non-bonded atom in a ligand. I f the l igand has any atom that 
is too close to another atom, we wi l l not evaluate the atom. 
Gibbs free energy 
I t is observable that material is more stable in its lowest energy 
form. The same principle applies to ligands and proteins. In 
molecular biology, the cause of higher energy is due to the repul-
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sion among atoms and hydrophobicity against water molecules. 
Determining interaction between water molecules could be costly 
and is not considered in our case. However, since to minimise 
the repulsion of a l igand is the same problem as to maximise the 
intra-molecular distance, each indiv idual in a generation w i l l un-
dergo the process of maximising the intra-molecular distance. 
lipophilicity 
A drug-like compound needs to have a balance between hy-
drophi l ic i ty and l ipophil icity. I t also required to be small enough 
such that i t could be absorbed and able to traverse cell mem-
brane. As we require high throughput in the post-processing 
step, the test is carried using a rule-based approach. We adopted 
Lipinski 's rule of five in the test [62]. There are four factors 
in this scheme: number of hydrogen donors, number of hydro-
gen acceptors, molecular weight and l ipophil icity. Regarding the 
number of donors and acceptors, i t is performed by counting the 
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number of oxygen, nitrogen and carbon in the structure. The 
weight of l igand is computed using the predefined atomic weight 
in a lookup table. Lipophi l ic i ty is represented using MLogP 
which is a rule-based method w i th correction. To maintain di-
versity, a ligand is only rejected if i t cannot satisfy any more 
than two rules. In case a ligand could only satisfy two or three 
rules，there is a 20% chance that the l igand is evaluated. 
5.3 Experiments 
In order to test SmartGrow comprehensively, we collected 3 re-
ceptors f rom PDB [63] and 8 unique in i t ia l ligands from PDB 
and ZINC [64]. From these data, 18 testcases could be formed, 
as detailed below. 
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5.3.1 Data Preparation 
Receptors 
We aim to select receptors that are of real-life importance. Glyco-
gen synthase kinase 3 beta (GSK3/3) is a theoretically promising 
pharmacotherapeutic target for the treatment of several human 
diseases, including type-2 diabetes [65] and Alzheimer's disease 
(AD) [66]. Efforts into discovering new inhibitors of GSK3/3 
never stop [67]. Therefore i t was included into our test data. 
H I V was also selected for its impact to human kind. Accord-
ing to the latest fact sheets of Wor ld Health Organization in 
2010, 33.4 mi l l ion people live w i th H I V / A I D S worldwide. H I V 
reverse transcriptase (H IV RT) and H I V protease (H IV PR), two 
v i ra l proteins residing in the body of the virus, assist the virus 
in infecting human cells. Researchers have spent over 30 years in 
discovering new inhibitors of H I V RT and H I V PR [68, 69, 70". 
Therefore, they were also included into our test data. 
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Total ly 3 receptors were collected f rom P D B for testing. They 
are glycogen synthase kinase 3 beta (GSK3/3) of P D B I D I J I B 
711 of resolution 1.80 A , H I V reverse transcriptase ( H I V RT) of 
P D B I D 2ZD1 [72] of resolution 1.80 A , and H I V protease (H IV 
PR) of P D B ID 3 K F N [73] of resolution 1.77 A. 
We manual ly extracted the 3 receptors out of their P D B com-
plexes, and queried CSA (Catalyt ic Site At las) [74] and relevant 
publications [71’ 67, 72, 68，69, 70, 73] for their possible b inding 
sites. 
Initial Ligands 
We aimed to select in i t ia l ligands tha t spread across wide ranges 
of free energies and molecular weights. The 3 ligands of P D B 
heterogeneous molecule IDs TRS, T27 and 4DX are respectively 
native ligands of GSK3从 H I V RT and H I V PR, hence they were 
included. 
Addi t ional ly , we retrieved 5 more ligands f rom Z INC, namely 
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Figure 5.1: Stick representations and molecular weights of the 8 unique initial 
ligands. From left to right: TRS, T27, 4DX, ZINC01019824, ZINC08442219, 
ZINC09365179, ZINC18153302, ZINC20030231. 
ZINC01019824, ZINC08442219, ZINC09365179, ZINC18153302, 
and ZINC20030231. The free energies and molecular weights of 
these 5 ligands spread across a wide range. 
Total ly 8 unique in i t ia l ligands were chosen, as shown in figure 
5.1. The 5 Z INC ligands were repeatedly used as in i t ia l ligands 
for each of the 3 receptors, resulting in a tota l of 18 in i t ia l ligands 
under the context of the 3 receptors. Note that even for the 
same Z INC in i t ia l ligand, its predicted free energy varies when 
docking to different receptors. 
SmartGrow has bui l t - in support for the chemical element of 
phosphorus. To test such capability, we picked an addit ional 
phosphorus-containing ligand named T F O from PDB, and gen-
erated ligands from T F O docking to H I V reverse transcriptase. 
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Fragment Library 
Ligands are mutated by appending new fragments f rom a frag-
ment l ibrary. There are two fragment libraries that accompanied 
w i t h the release of AutoGrow, namely the small-fragment and 
the large-fragment libraries. We tested both libraries internally, 
and noticed early convergence when using the large-fragment li-
brary, which was quite problematic for testing purposes. So we 
focused on the small-fragment l ibrary, which is made up of 46 
fragments. They are small in size, having 3 to 15 atoms and an 
average of 9.6 atoms w i t h a standard deviat ion of 2.8 [75.. 
5.3.2 Experimental Methods 
We tested SmartGrow v l . l 4 and compared i t w i t h AutoGrow 
2.0.4，the most recent versions of both programs at the moment 
this thesis was composed. The parameter settings for AutoGrow 
and SmartGrow are listed in table 5.1. The default values for 
AutoGrow were retained, i.e. 10, 20, 20, and 8 for the number 
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of elitists, children, mutants, and generations, respectively. The 
docking frequency of AutoGrow is fixed to 1 because evaluation 
is always done by docking in AutoGrow. The maximum number 
of atoms was set to 80 because we noticed f rom in i t ia l tr ials that 
the generated ligands of f inal generation consisted of around 70 
atoms but their molecular weight already exceeded 500 Da. To 
make a fair comparison, the settings for SmartGrow were set to 
be identical to AutoGrow except for the number of generations 
and docking frequency. Since SmartGrow supports evaluation 
by scoring only, its docking frequency was set to 3 to examine 
this special feature. Meanwhile, the number of generations in 
which evaluation is done by docking is set to 8, the same as 
AutoGrow. Hence the number of generations for SmartGrow 
was set to 24. 
So far we have collected 3 receptors, each of which is associ-
ated w i t h 6 in i t ia l ligands. Therefore there are 18 testcases in to-
tal. Since genetic algori thm is stochastic, we ran AutoGrow and 
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Program AutoGrow SmartGrow “ 
Number of elitists 10 10 
Number of children 20 20 
Number of mutants 20 20 
Number of generations 8 24 
Docking frequency 1 3 
Max number of atoms 80 80 
Table 5.1: Parameter settings for AutoGrow and SmartGrow. Elitists refer 
to the best ligands of a generation that will survive directly into the next 
generation. Children refer to ligands generated by crossover. Mutants refer 
to ligands generated by mutation. 
SmartGrow for 9 times for each testcase under the parameter 
settings shown in 5.1, simultaneously on 6 L inux machines w i th 
Ubuntu 10.04.1 x86_64, Dual Intel Xeon Quad Core 2.4GHz, and 
32GB R A M . Each AutoGrow execution and SmartGrow execu-
t ion cost approximately 3 hours and 2.4 hours respectively on 
average. 
5.4 Results 
5.4.1 Binding Pose 
In order to validate the correctness of ligands generated by 
SmartGrow, we picked out the best l igand from each testcase 
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and visualized i t in complex of its corresponding receptor. Here, 
the best l igand refers to the one that have the lowest free energy. 
Figure 5.3 demonstrates one particular testcase. 
The in i t ia l l igand ZINC01019824 does not form any hydrogen 
bond w i t h GSK3/3, as shown in figure 5.4.1. Its free energy is -6.9 
kca l /mol and its molecular weight is 194 Da. The best l igand 
generated by AutoGrow forms 4 hydrogens bonds, interacting 
w i t h Ty r l 34 , Prol36, Gln l85, and Asnl86 of GSK3/3, as shown 
in figure 5.4.1. I ts free energy is -11.9 kca l /mol and its molecular 
weight is 572 Da, 72% lower in free energy and 195% larger 
in molecular weight than the in i t ia l ligand. The best l igand 
generated by SmartGrow forms 9 hydrogens bonds, interacting 
w i t h Aspl33, Ty r l34 , Prol84, Gln l85 and Asn l86 of GSK3/3, 
as shown in figure 5.4.1. Its free energy is -11.2 kca l /mol and its 
molecular weight is 505 Da, 62% lower in free energy and 160% 
larger in molecular weight than the in i t ia l ligand. 
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Figure 5.2: Average free energies and molecular weights of the best 5 ligands 
generated by AutoGrow and SmartGrow of each generation. Generation 0 
refers to the initial ligand. Blue circles: average free energies of the best 5 
ligands generated by AutoGrow. Green diamonds: average free energies of 
the best 5 ligands generated by SmartGrow. Red squares: average molecular 
weights of the best 5 ligands generated by AutoGrow. Purple triangles: 
average molecular weights of the best 5 ligands generated by SmartGrow. In 
the first 6 sets of curves ((a)-(f))，initial ligands dock to glycogen synthase 
kinase 3 beta. In the middle 6 sets ((k)-(l)), initial ligands dock to HIV 
reverse transcriptase. In the last 6 sets ((m)-(r)), initial ligands dock to HIV 
protease. 
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m^ 
Figure 5.3: The initial ligand and the best ligands generated by AutoGrow 
and SmartGrow, in the testcase of ZINC01019824 docking to GSK3/3. Hydro-
gen bonds are represented as dotted green lines. From left to right: Resulting 
complex of initial ligand, ligand by AutoGrow, ligand by SmartGrow. 
5.4.2 Free Energy and Molecular Weight 
The goal of fragment-based growing strategy is not to generate 
one single best ligand, but a populat ion of drug-like ligands to 
be shortl isted for further verifications by wet lab experiments. 
Therefore i t is more meaningful to dig into the average per-
formance of the best several ligands. Hence the free energies 
and molecular weights of the best 5 ligands were plot ted against 
generation number in figure 5.2. 
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Figure 5.4: Average execution times of AutoGrow and SmartGrow, catego-
rized by GSK3/^, HIV RT and HIV PR. 
5.4.3 Execution Time 
We also measured the execution times of AutoGrow and Smart-
Grow. Since all the testcases were run for 9 times, their average 
execution times are shown in figure 5.4. 
5.4.4 Handling Phosphorus 
AutoGrow does not support phosphorus, which is a very com-
mon chemical element found in drugs. In contrast, SmartGrow 
has bui l t - in support for phosphorus. To examine such capabil-
ity, from P D B we picked TFO, a phosphorus-containing in i t ia l 
ligand, as an addit ional testcase. The result is not shown in this 
report. 
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5.5 Discussions 
Through visualizing the generated ligands in complex of their re-
spective receptors, we found that they are chemically valid, and 
we are thus of fu l l confidence about the correctness of Smart-
Grow. A n example testcase is demonstrated in figure 5.3. The 
best ligands generated by SmartGrow have significantly lower 
molecular weights than those generated by AutoGrow, hence 
they are more likely to optimize into drugs. 
Regarding the average free energies and molecular weights of 
the best 5 ligands generated by both programs, as shown in fig-
ure 5.2, for most of the cases SmartGrow displays a comparable 
free energy curve, while its molecular weight curve is remarkably 
lower than AutoGrow, and seldom exceeds 500, thanks to the 
guidance of Lipinski 's rule of five and the 'spl i t ’ operator. 
Regarding the execution t ime, as shown in figure 5.4, Smart-
Grow outperforms AutoGrow for 14 out of 18 test cases. For the 
CHAPTER 5. DRUG DESIGN 140 
testcase w i t h GSK3y0 as the receptor and ZINC20030231 as the 
in i t ia l l igand, SmartGrow runs as much as 119% faster than Au-
toGrow. For the testcase w i t h H I V RT as the receptor and T27 
as the in i t ia l l igand, although SmartGrow requires 27% more 
t ime, the generated ligands have lower free energies, as shown 
in figure 5.2(g). Averaging all the 18 testcases, i n general Smart-
Grow executes about 30% faster than AutoGrow. 
5.6 Conclusion 
We have developed a new algor i thm called SmartGrow, an ef-
ficient too l for computat ional synthesis of potent ligands for 
drugs. SmartGrow has inheri ted the exist ing muta t ion and 
crossover operators and we have invented two new genetic oper-
ators，namely split and merging. The split operator ensures that 
ligands w i l l not exceed the upper bound for the molecular weight 
for druggabil i ty. The merging operator is basically a reversed 
operator of split which accelerates l igand growing. SmartGrow 
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implements Lipinski 's rule of five to ensure draggabil i ty. The 
comprehensive results show that SmartGrow outperforms Au-
toGrow in terms of free energy, molecular weight and execution 
t ime. 
• End of chapter. 
Chapter 6 
Interactive Drug Design 
Interface in Virtual Reality 
Summary 
A drug design algorithm incorporating human intell i-
gence interactively achieved better efficiency and accu-
racy. 
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6.1 Introduction 
6.1.1 Motivation 
The momentum in searching for compounds of medical uses con-
tinues to grow as diseases are more diff icult to cure owing to drug 
resistance. Out of the possible configurations of the molecules 
which may have medical purposes[13], only a minor i ty of the 
molecules were synthesized and exploited. I t becomes crucial to 
design new molecules which can be of medical values but not 
explored. Computat ional methods have been employed because 
of low cost and high efficiency. 
There are numerous computational techniques, mainly fragment-
based and diversity-oriented, to generate drug candidates for 
wet-lab experiments [1, 2]. Fragment-based method constructs 
a l ibrary of structural ly diverse small molecules that could be-
come fragments of active drugs [3, 4]. The drug candidate starts 
w i t h low aff inity for the target and is systematically altered 
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and enlarged, generating high affinity，drug-like lead compound. 
Diversity-oriented method produces a l ibrary of s t ructural ly di-
verse drug-like compounds, usually f rom common intermediates[5, 
6]. The compounds are then screened and high aff in i ty candi-
dates are optimised for further analysis. The accuracy of both 
strategies rely on the screening procedure, which could be a 
docking program in a recent approach[39'. 
I n addressing the accuracy issues，there are interactive ap-
proaches which enable opt imisat ion to the compound using the 
user's knowledge about structure-act iv i ty relationship[40]. The 
algor i thm visualises a set of drug candidates for the user to 
choose f rom and generate new candidates based on their choice 
using evolut ionary algori thm. I t overcomes the diff icult ies in 
creating the fitness funct ion to assess drug design. However, i t 
considers solely on the structure of the drug candidates while 
the protein target is often known especially for pharmaceutical 
companies. 
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6.1.2 Objective 
Given a l igand-protein complex, we aim at opt imising the l igand 
to interact more readily w i t h the protein target through human 
interaction. Human interaction means a user evaluates, modifies 
and manipulates the l igand-protein complex and the computer 
verifies new ligand conformations according to the actions. 
6.1.3 Overview 
We propose an interactive algori thm for drug design w i t h a 
known protein target. Visualisation plays an important role in 
displaying l igand-protein structure in 3D. The user can then in-
vestigate the structure and determine whether a drug candidate 
is viable. Whi le there are good visualisers such as JMol and lig-
and editors by MolSoft, manipulat ing a drug candidate around 
requires adequate depth information. V i r tua l reality enables im-
mersive experience to the user where conventional visualisation 
techniques cannot. The program generates a set of drug candi-
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dates by evolutionary algorithm and refined by chemical rules 
and docking. The user gives feedback by translat ing or rotat-
ing the candidates and remove them if found unsuitable. Our 
study shows the resulting lead compound is lighter in molecular 
weight which can be more readily absorbed and has comparable 
affinity to the automatic method. 
The detailed design and algorithm is presented in section 6.2. 
Experiments are described in section 6.3. A discussion on the ad-
vantages and improvements of the interactive approach is given 
in section 6.4. 
6.2 Methods and Design 
The program consists of an interface which displays the ligand-
receptor pair in v i r tua l reality and a computational module to 
provide feedback. We first explain the algorithms in the compu-
tat ional module and then describe the features of the interface. 
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6.2.1 Hybrid Drug Synthesis 
The drug synthesis algori thm employed in our program com-
bines the strength of fragment-based and diversity-oriented ap-
proaches. The synthesis algori thm is adopted from the design 
and refinement module and is modified to support new fea-
tures. A diversity-oriented approach creates structural ly diverse 
molecules w i t h their molecular masses usually close to those of 
drug-like compounds. In addition, i t explores molecules that 
escape the attent ion of human or even nature. A fragment-
based approach produces numerous sets of compounds not rep-
resented in existing libraries, f i l l ing the gap of 'chemical space'. 
I t is suggested that tremendous amount of compounds can be 
represented in a l ibrary of few fragments. 
The program accepts a small molecule and a receptor of Pro-
tein Data Bank (PDB) format. The small molecule is then be 
optimised to bind into the receptor. The program uses a frag-
ment l ibrary ranging from hydroxide to benzene to add onto the 
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small molecule. Evolutionary algorithm (EA) is employed to 
generate mult iple instances of the small molecule and maintain 
diversity. I t is based on biological principles such as natural se-
lection and usually involves mutat ion and crossover operations. 
There are four operators inherited from the previous module, 
namely, mutat ion, crossover, merge and split. A brief descrip-
t ion of the operators are as follows. 
(1) Mutation: This replaces a hydrogen atom in a small 
molecule w i th a random fragment from the library. A hydro-
gen atom on the fragment is removed such that a non-hydrogen 
atom is attached to the small molecule. The small molecule is 
optimised by rotat ing the fragment to achieve min imal torsion. 
(2) Crossover: Two small molecules are selected and ex-
change some of their fragments. The implementation resembles 
genetic programming that a subtree of two different molecules 
are selected and swapped. The small molecule is in a graph-
based representation and cannot contain incomplete cycles. Thus, 
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when a random atom on the fragment is selected, excluding the 
common in i t ia l compound, all dependent atoms are checked anc. 
selected for the exchange. Two small molecules are optimised 
and generated. 
(3) Merge: A n operation similar to crossover that two small 
molecules are chosen. A l l fragments on one of the small molecule 
are transferred to the other small molecule, removing some hy-
drogen atoms. Only the larger small molecule is returned, de-
creasing the number of small molecules in the set by one. 
(4) Split: This transfers some randomly chosen fragments 
on a small molecule to the in i t ia l common compound. The va-
lences of the small molecule which loses fragments is corrected 
by adding hydrogen atoms. Two small molecules are optimised 
and returned, increasing the number of small molecules in the 
set by one. 
For the implementation of the four operators, please refer to 
the previous chapter Drug Design. Apar t f rom the mentioned 
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operators, there are two special methods to produce larger vari-
ance to the small molecules which are invoked upon user selec-
t ion and suitable conditions. 
Join Ring: This is an advanced mode of mutat ion that the 
r ing in the fragment is joined to a r ing on the small molecule, 
forming consecutive rings. Both the fragment and the small 
molecule must contain r ing structures to perform. Two adja-
cent atoms on the r ing are checked to find a matching pair in 
another ring. A tom pairs can only be matched provided that 
their bond difference is w i th in threshold and the pairs are of 
same atomic types. I f no r ing can be joined, the usual mutat ion 
is carried instead. The implementation of the jo in r ing method 
is described in the following pseudo-code. 
Decrease Bond Order: I f there is a double or t r ip le bond 
in the small molecule, the order of that bond is decreased by 
one. By decreasing the order of a bond, a double bond becomes 
a single bond; a tr iple bond becomes a double bond. Hydrogen 
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Algorithm 4 Joining Ring Structures of Two Compounds C“ Cj 
1： if Ci or Cj have no ring then 
2： return -1 
3： end if 
4: Exclude common structure 
5： Randomly choose adjacent atoms pairs a}, of G Ci and a], aj € Cj 
6： if aj, af a], then 
7： Repick 
8： end if 
9： if (aj - a\f 一 (a] 一 a计 > 0.25 then 
10： Repick 
11： end if 
12： if No possible pairs 100 times then 
13： return -1 
14： end if 
15： Atoms connecting a], aj connects to aj, of instead 
atoms are added to correct the valences. The small molecule is 
optimised by orienting atoms in new position, reducing overall 
free energy. The resulting small molecule contains more bonds to 
add fragments which encourages diversity. The implementat ion 
detail is explained below. 
Algorithm 5 Decrease Bond Order in Compound C 
1： Create atom set to modify A = ai £ C 
2: for a i e C do 
3： if di part of ring then 
4: Remove a^  from A 
5: end if 
6： end for 
7： Randomly choose a pair in A 
8： Replace bond 1 order lower 
9： Optimise placement 
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Using the operators and methods mentioned, a set of small 
molecules is generated. The user can investigate the structures 
of the generated small molecules. However, i t usually takes tens 
of different small molecules for the evolutionary algori thm to 
work well. The user may not want to explore the whole pop-
ulation. I n addition, the decision of the user can benefit f rom 
binding aff inity between the small molecules and the receptor. A 
docking algori thm is integrated as the fitness funct ion of the evo-
lut ionary algorithm. A n external docking program AutoDock 
Vina[58] is integrated because i t is fast and relatively accurate. 
Its bundled tool, MGLTools, computes the flexible side chains 
and part ia l charges of the small molecule and receptor. 
A compound follows certain chemical rules. I f the graph rep-
resentation is evolved freely, invalid molecule may arise. The 
Lipinski 's rule of five[62] is applied to check the val id i ty of the 
resulting small molecules evolved. The rules describe the num-
ber of acceptors, donors, molecular weight and solubil i ty of a 
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compound to be drug-like. 
Whi le the evolutionary approach can work on its own, there 
are several disadvantages. Firstly, the docking method may not 
be accurate enough in optimisation and sometimes incorrectly 
estimates the potency of the lead compound. The docking pro-
gram evaluates on the free energy of the binding system that 
opt imisat ion according to this metric does not often result in 
a functional l igand-protein binding system. Secondly, the com-
pounds are diff icult to compare. I t is necessary to compare the 
physical and chemical properties among compounds which can-
not simply represented by similar i ty index or subgraph differ-
ences. Lastly, evolutionary algori thm requires parameters tun-
ing to work well. For this complex problem, the number of 
parameters is large which does not appeal to the users. In ad-
dit ion, i t is more effective to adaptively adjust the parameters 
based on situations. 
We, therefore, introduce an interactive solution incorporating 
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human intelligence. The fitness and similari ty are decided by 
the users using their expert knowledge. The parameters of the 
evolutionary algorithm are adjusted based on the feedback of the 
user. This interactive approach relies on a rigorous visualisation 
implementation. 
6.2.2 Interactive Interface in Virtual Reality 
Realistic visualisation is important in biomedical research, es-
pecially in the field of drug design. V i r tua l reality (VR) envi-
ronments allow a detailed inspection on molecular structure and 
offer a different quali ty than standard 3D representation. 
The interface is developed in C + + and OpenGL program-
ming language which is portable across platforms. The interface 
can visualise PDB format in standard 3D, red-and-blue stereo 
or shutter stereo mode. When paired w i th the drug design algo-
r i thm, the interface provides feedback to the user and computes 
the parameters for the algorithm. The standard 3D visualisa-
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t ion enables users wi thout equipment to produce v i r tua l reality 
environment to use the drug design algorithm. 
3D visualisation techniques 
3D visualisation is usually implemented through the technique 
stereoscopy which creates the il lusion of depth. This technique 
presents two images separately, each has slight disparity from 
the other, to the left and right eye of the viewer. Bo th images are 
perceived in the brain as a single image, the difference between 
bo th images produces the sense of depth. The offset images are 
slightly rotated version of the original image. The left offset 
image is created by rotat ing the original image to the left along 
the vert ical axis; The right offset image is created by rotat ing 
the original image to the right along the vertical axis. To make 
each eye of the viewer sees a different image, special glasses are 
used to fi l ter the offset images from a source. 
There are two viewing approaches which affect the perception 
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Figure 6.1: Illustration on different parallax approaches 
of the resulting 3D image. They are known as parallel parallax 
and crosseye parallax. The principle of both approaches is il-
lustrated in Figure 6.1. The solid line represents the viewing 
approach of parallel parallax and its focus is marked by a dot. 
The dashed line represents the viewing approach of crosseye par-
allax and its focus is marked by a dot. In parallel parallax, the 
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viewer's left eye sees the left offset image and the r ight eye sees 
the r ight offset image. The 3D image is reconstructed behind 
the viewing plane that the viewer w i l l perceive the 3D image 
inside the displaying medium. The dispari ty between the offset 
images can be small to create a strong paral lax effect. I n cross-
eye paral lax, the viewer's left eye sees the r ight offset image and 
the r ight eye sees the left offset image. The viewer perceives a 
focus in front of the viewing plane such that the viewer thinks 
the object in the image is outside the displaying medium. To 
create a strong parallax effect, the dispari ty between the offset 
images need to be large. I n Figure 6.1，the effect of paral lax is 
described and measured by the distance f rom the focal point to 
the viewing plane. The parallax effect is stronger using paral-
lel v iewing technique than crosseye viewing technique using the 
same set of offset images. 
The classic way to present the offset images is pu t t i ng them 
side-by-side, so the viewer can see two images of the same ob-
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ject similar to viewing through a binocular. The viewer needs 
to part i t ion the images to achieve binocular vision and avoid 
distraction. Later approaches overlap the offset images that the 
viewer can perceive a single images wi thout glasses. To view 
the offset image from the overlapped image, special methods 
and glasses are required. Two common methods of stereoscopy, 
complementary colour anaglyph and active shutter, are imple-
mented in the interface. 
Complementary colour anaglyph normally use a pair of filters, 
red and cyan, to fi lter out an offset image. Since red and cyan 
are complementary colours, when the red and cyan filters are 
put together, the viewer cannot see l ight passing through and 
the image appears black. I f red filter is employed for the left eye 
and cyan filter for the r ight, the left offset image is processed to 
remove cyan colour so that i t cannot be seen by the right eye. 
A similar procedure applies to the r ight offset image to remove 
red colour. This technique quickly becomes popular because of 
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low-cost red-cyan glasses. The resulting images using anaglyph 
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Figure 6.2: Procedure in creating 3D effect using anaglyph (left) and active 
shuttering (right) 
Active shutter is known as 'active' because energy is required 
to control l ight passing through the glasses and synchronise w i th 
the display. This technique uses the concept of alternative frame 
sequencing. The offset images are display alternatively on the 
screen. When the left offset image is displayed, the glasses syn-
chronise w i t h the control device and block l ight to the r ight eye. 
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The display device needs to show the alternating images fast 
enough otherwise the viewer w i l l perceive flashing 
• 
Figure 6.3: Stereo effect in anaglyph mode (red-and-blue). Using a spectacles 
with red and blue filter on each side, the disparity between the two super-
imposed DNA creates a perception of depth. The DNA appears in white in 
stereoscopy. This figure shows the effect without the spectacles. 
In Figure 6.2, the concept of creating 3D images is i l lustrated. 
Using the anaglyph technique, offset images derived f rom the 
original image undergo colour filtering. Both offset images are 
overlapped to form a single image which is st i l l picture and can 
be used in books. Using the active shuttering technique, offset 
images are arranged in-order and displayed alternatively. The 
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Figure 6.4: Stereo effect in shutter mode. Superposed images are displayed 
alternatively in temporal frames. The spectacles synchronise with the mon-
itor such that each eye perceive the correct image. This figure shows the 
effect without the spectacles. 
special glasses need to synchronise w i t h the display sequence to 
achieve 3D perception. 
The red-and-blue stereo mode (Figure 6.3) is a compromise in 
visualising structures in single colour which works on common 
monitors. I t could display depth information better than the 
standard 3D which is crucial when judging the binding position. 
The shutter stereo mode (Figure 6.4) requires a high frequency 
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monitor and special spectacles, but provides the best experience. 
Molecules visualised in this mode are rich in colour and depth 
information is presented precisely. Both stereo mode employs 
crosseye parallax to allow more detailed investigation inside a 
protein. 
Display Modes 
There are several display styles the interface supports which vi-
sualises different levels of information. The supported styles in-
clude D N A backbone model, ball-and-stick model, cartoon rep-
resentation and van der Waals filling model. The van der Waals 
filling model requires surface mesh computat ion which can take 
up to half a minute upon the in i t ia l rendering. Af ter the in i t ia l 
rendering, all models can be manipulated in real-time in stereo 
on common machines. 
The ball-and-stick model (primary structure) is used to dis_ 
play the chemical aspects of the molecules. This is the only 
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model available to the small molecules. This mode is used to 
visualise the bonding between a small molecules and its recep-
tor. Each atom type has its own colour coding such that the 
view can easily identify them. Different orders of bonding are 
also visualised. Atoms connected by a double bond is visualised 
w i t h two connections. Even the part ia l bonds are displayed by 
dashed lines among atoms in a protein. I n this mode, computa-
t ional expenses can be reduced by displaying the bonds only. 
The cartoon representation (secondary structure) reveals in-
formation on the shape and size of a protein. This mode uses 
simplif ied symbols such as arrows and ribbons to represent beta 
strands and alpha helices of the protein. Most of the t ime, infor-
mat ion at the atomic level is not necessary for protein analysis. 
Protein is usually described using amino acids, also known as 
residues. Some residue patterns form a stable structure and 
resemble certain shapes. Residues patterns are represented by 
helices and strands, other residues form a chain by interpolat ing 
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through their centres. 
Figure 6.5: Cartoon representation of 3XME. Alpha helices and beta strands 
are represented by ribbons and arrows respectively. The ligand IFl is pre-
sented by ball-and-stick model inside the protein 
The van der Waals f i l l ing model (surface representation) visu-
alises each atom in the protein using their van der Waals radius. 
This mode presents surface information of the protein which al-
lows investigation on the binding sites. To calculate the surface 
of the protein, a number of vertices around the van der Waals 
radius of the atoms are sampled. I f a vertex is not w i th in any 
van der Waals radius of the other atoms, i t is used to interpolate 
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the surface of the protein. The process of selecting vertices and 
interpolat ion is computat ional intense. However, once the inter-
polat ion is completed, rendering the protein is efficient enough 
to achieve real-time interaction. 
The display capabilities of our interface may not be compre-
hensive as the mature display tools such as JMol, which supports 
a variety of visualisation choices. When compared w i t h the edit-
ing tool f rom Molsoft, their tool has more modif icat ion options 
and a well-established evaluation function. Nevertheless, the in-
terface we developed has more features than the existing tools. 
I t includes mult ip le stereo modes for different hardware configu-
rations. In addit ion, our tool evaluates mult iple drug candidates 
and assigns fragments automatically which can reduce the effort 
of the user. 
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Figure 6.6: Surface model of 3XME. The protein is coloured according to its 
chains and a binding site is clearly shown. 
Linking with Drug Design Algorithm 
The interface has a collision detection algori thm integrated to 
support dragging by the user. The user can select the protein by 
atom, residue or chain levels. I t is done by directly clicking on 
the visualised proteins or the names in the list which contains the 
sequences in text form. In addition, bonding between the small 
molecule and the protein can be highlighted. The residues which 
CHAPTER 6. INTERFACE IN VIRTUAL REALITY ‘ 167 
bond direct ly w i t h the small molecule is shown normal ly while 
the other fades out. The bonds are calculated using hydrogen 
bond or distance criteria. 
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Figure 6.7: Interface of the interactive drug design program. Table on the 
right displays atom information in a hierarchy. Table on the bottom shows 
information in group such as chains and residues. The hydrogen bonds be-
tween the ligand and protein 3XME are displayed in the main window, with 
non-interacting residues faded out 
When the interface is used w i t h the drug design algori thm, 
the in i t ia l small molecule and the receptor must be specified. 
Two parameters, the number of small molecules generated n 
and investigated Cutoff, are defined by the user. A sufficient 
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number of small molecules to be generated can encourage diver-
sity among the population and reduce the chance of premature 
convergence. The user only needs to investigate a port ion of the 
generated small molecules. A subset is selected for investigation 
according to the affinity, calculated by the docking program, and 
the molecular weights of the small molecules. The in i t ia l popu-
lat ion is then created by mutat ing the specified small molecule. 
The flow of the design is briefly described in the following pseu-
docode. 
Algorithm 6 Optimising compound interactively 
1: Choose initial compound L and protein target P 
2: Drag L to binding pocket, specify test region 
3: for User continues do 
4: Generate candidates L i . . . Ln, assess binding energy against P, where 
n is population size 
5: Rank Li according to binding energy, where Li has lowest energy 
6: if L, I z < Cutoff then 
7: Display Li for interaction 
8： end if 
9: if Li accepted by user then 
10: Adjust parameters 
11： end if 
12： end for 
13: return Best candidate Li 
Dur ing each generation, the user investigates a set of small 
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molecules and decides whether to accept or remove them. Only 
one l igand-protein pair can be investigated at a t ime due to the 
complexity of the structure to be drawn. The user is assisted 
by a variety of information to make the decision. The statistics 
of the small molecule, including number of donors, acceptors, 
estimated logP and molecular weight, are displayed. The docked 
structure is visualised in v i r tua l reality w i th possible hydrogen 
bonds drawn. The structure can be rotated and zoomed in for 
more details. The user can cycle through different model styles 
and highlight the interacting residues. The small molecule can 
be dragged and rotated, hydrogen bonds are updated in real-
t ime. The user can specify to use the modified structure in the 
next generation of the drug design algorithm. 
Based on the decision of the user, parameters of the drug 
design algori thm is dynamically calculated. Each ligand for in-
vestigation carries a weight according to binding energy given by 
Wj = where Ng is the number of ligands for investigation 
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and j is the rank of the ligand. These parameters are changed 
each generation depending the investigation result. When the 
user removes a major i ty of the small molecules for investigation, 
the mutat ion rate becomes high in order to create structural ly 
diverse small molecules, which covers more 'chemical space'. In 
contrast, when the user accepts most small molecules, crossover 
is encouraged to create similar compound of the accepted ones. 
The molecular weight also plays a role in changing the param-
eters. There is an impl ic i t molecular weight in the algorithm, 
which is the average of molecular weights of the small molecules 
for investigation. The projected molecular weight, which is used 
to control mutat ion rate and crossover rate, is altered by the de-
cision of user and is given by 
顺 = + 悬 + 50， 
where MWj is the molecular weight of ligands selected by the 
CHAPTER 6. INTERFACE IN VIRTUAL REALITY ‘ 171 
user, 0 otherwise. Af ter the user accepts a certain number of 
small molecules, their average molecular weight is calculated. I f 
the new weight is smaller than the impl ic i t weight, i t means that 
the user prefers smaller compound. The split operator w i l l be 
invoked more often. The opposite applies that merge operator 
is used more often when the averaged weight is larger than the 
impl ic i t weight. The two advanced methods, jo in r ing and de-
crease bond order, need to be instructed by the user and are not 
used normally. The program can be stopped any t ime when the 
user is satisfied w i t h the generated small molecules. 
6.3 Experiments and Results 
6.3.1 Data Preparation 
We conducted experiments on the program using several recep-
tors f rom P D B and compounds from the Z INC database[64]. We 
wi l l explain one of the experiments which illustrates the idea of 
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the interactive drug design algorithm. The receptors chosen are 
Human Entrovirus 71 3C protease and heat shock protein. Their 
corresponding PDB ID are 30SY and I G M E . A benzene r ing 
was chosen as the in i t ia l l igand for the receptors since they do 
not have known inhibitors. Their putative binding sites are re_ 
solved using Autodock Vina. The fragment l ibrary used for both 
programs was the same which contained 46 small fragments and 
large fragments from ZINC database. 
6.3.2 Experimental Settings 
Our work SmartGrow was chosen for comparison as the auto-
matic design algorithm. This algori thm is fragment-based and 
utilises evolutionary algorithm. For the interactive program, a 
populat ion of 30 was set. The number of small molecules for in-
vestigation was 6. For the automatic program, i t used the same 
populat ion size. The number of elitists was set to 6. We set 
the number of molecules produced by mutat ion and crossover, 
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where they were set to 16 and 8 respectively. Due to human 
efforts, bo th programs were executed eight generations and we 
only interacted w i th the first generation of small molecules. We 
run both programs 3 times for the receptor 30SY. The test are 
run on a dual-core machine. 
6.3.3 Results 
The results of both tr ials are listed in the following table. 
Automatic Interactive Difference 
Affinity (30SY) 
Average -9.42 -10.83 +14.97% 
Best -10,1 -11 +8.91% 
Time(s) 26789 26150 -2.39% 
Affinity (IGME) 
Average -9.07 -11.3 +24.59% 
Best -9.7 -11.3 +16.49% 
Time(s) 32178 12516 -61.10% 
Table 6.1: Comparison on the affinities of resulting drug candidate produced 
by automatic and interactive approaches. The execution time of both ap-
proaches are also compared. 
The program was run to the end which took about seven 
hours in case of EV71 protease test set. The best compound 
produced by the interactive method has a binding energy of -11 
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kJ and the best by SmartGrow has a binding energy of-10.1 kJ. 
Consider the averaged binding energy of each approach, Smart-
Grow has an average of -9.42 kJ and w i th human intervention, 
leaded to a better energy level of -10.83 kJ. The aff ini ty of the 
interactive approach was 8.9% better over the best candidate 
and 15% better averaged over the automatic approach. The dif-
ference are more significant when the programs are tested on the 
heat shock protein. The automatic method took almost night 
hours to complete the task. The interactive method took only 
three and a half hour to complete, which is a significant 60% re-
duction in t ime. The quali ty of solution was also higher than the 
automatic approach. In this case, the design process converges 
to a very similar drug candidate, resulting in same affinity. The 
best and averaged affinities of the drug candidates from the in-
teractive approach were 25% better and 16% better than thier 
counterparts respectively. 
In figure 6.8, we show an example of the best drug candidate 
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Figure 6.8: Putative binding site on EV71 protease, (a) Initial scaffold in 
binding site, (b) Resulting lead candidate by the automatic algorithm, (c) 
Resulting lead candidate by the interactive algorithm. 
f rom 3 0 S Y of the two programs. The comparison indicates that 
the automatic program misplaced the binding region of the ini-
t ia l scaffold. Prom the middle figure, the binding pocket at the 
top is the in i t ia l binding region but the compound optimised 
did not lie in the region. The interactive approach extends the 
in i t ia l compound that the optimised compounds bind two bind-
ing pockets, resulting in much better binding energy which is 
-3.8 kJ at first. In addit ion, the resulting compound of the in-
teractive approach contained large consecutive rings not in the 
in i t ia l compound which is diff icult to achieve in many automatic 
methods. This result clearly shows the strength of the interac-
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t ive approach that the ligand can be manipulated towards the 
binding site, especially when there are mult iple binding site on 
the receptor. 
6.4 Discussions 
In this paper, we have described an interactive approach over 
the evolutionary algori thm for drug design. The graph represen-
tat ion preserves most of the information available in the struc-
tures. I t is also suitable for fragment-based methods which have 
the potential benefit of easier synthesis. We used standard PDB 
format for displaying and processing which effectively utilises 
online resources. In addition, the interface can be used as a 
standard visualiser to display structure in v i r tua l reality when 
not paired w i th the drug design algorithm. We have achieved 
real-time interaction w i th the molecule in stereo mode, while 
the evaluation process may take longer t ime. 
Adopt ing an interactive approach, we overcome the most dif-
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ficult aspect in evolutionary algori thm for drug design, creating 
the appropriate fitness function. The evolutionary algor i thm is 
specially designed to dynamically adjust itself each generation 
by the decision of the user. We have decided not to display 
all the small molecules in the populat ion because the user may 
not want to screen tens or hundreds of compounds before pass-
ing them back to the algorithm. Instead, a por t ion of small 
molecules, which the algori thm thinks they are good, are vi-
sualised for investigation. The parameters of the evolutionary 
algor i thm are calculated based on the decision about the selected 
set of small molecules. Through this design, we have abstracted 
the complicated parameter tuning process into simple reasoning. 
There are many advantages to user interaction. The most 
attract ive advantage to drug design is the feedback from the 
users can produce compounds which can be synthesized more 
easily in laboratory. W i t h more expert knowledge, the result-
ing compounds wi l l be more likely to be synthesisable. Another 
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advantage is the user can use whatever domain knowledge they 
have，whereas the developers may not possess. I t is part icu-
lar ly di f f icult to assume all required knowledge is integrated be-
forehand. A th i rd advantage is user-friendliness. Tuning the 
evolut ionary algor i thm can be tedious when there are a lot of 
parameters. The interactive approach reduces the tun ing pro-
cess to simple questions: whether to accept a small molecules or 
use certain methods. Nonetheless, using an interactive program 
can be more t ime-consuming than an automatic approach. The 
outcome may not be objective which depends on the perception 
of the user. 
Considering the power of feedback of the users, we have planned 
to allow greater flexibility in the interface such as real-t ime mod-
i f icat ion to the small molecules. A t the moment of wr i t ing, only 
translat ion and rotat ion are available to the user. W i t h more 
explicit chemical rules implemented, the user can modi fy atoms 
or fragments on the small molecules. In addit ion, w i t h recent ca-
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pabi l i ty to display in v i r tua l reality on webpages, i t is beneficial 
to have a web-front which encourages a larger user base. 
6.5 Conclusions 
We have designed and implemented an interactive approach to 
the drug design. Through visualisation on the docked structures 
in v i r tua l reality, domain experts can investigate and manipulate 
visually w i t h higher precision. Incorporat ing human intelligence 
in the fitness function, we overcome difficulties associated w i t h 
physico-chemical properties of compounds. I t also combines the 
domain knowledge of the user and processing power of comput-
ers. 




A conclusion on the IDS framework and future directions 
are given. 
The ID3 framework provides a unified interface for the de-
sign and verification of compounds towards a targeted protein. 
The algori thm on protein function prediction is bui l t on a novel 
data structure, heterogeneous vector, enabling competit ive per-
formance against current approaches w i th less information. I t 
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allows querying of proteins w i th l i t t le knowledge about the struc-
ture and provides functional clues by matching similar protein 
clusters. In addit ion, the algori thm is scalable and produces 
better result ing when more protein samples are given. Af ter 
ident i fy ing the target protein of desired function, an interacting 
compound is created using a fragment-based approach. 
A new algori thm called SmartGrow has been implementec. 
using evolutionary algori thm that preserves diversity and pro-
duce near opt imal solution. The algori thm is at tuned to the 
graph structure of compounds and mimics experimental meth-
ods that medical active fragments are the bui lding blocks. We 
have shown that our algori thm outperform the latest similar ap-
proach, by accounting physico-chemical properties, in terms of 
execution t ime, aff inity and molecular weight. 
Concerning the computational model may not best describe 
the interaction between the drug candidates and the target pro-
tein, an interactive interface in v i r tua l reality has been devel-
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oped to let users verify their designs. Structure investigation 
in v i r tua l reality is immersive and more precise than plain 3D 
approach. The interface provides real-time force calculation and 
collision detection that the user can t r y binding poses which have 
not been visited by the design algorithm. The user can provide 
feedback to the system and SmartGrow can further optimise 
the drug candidates. Through the support of several methods 
and human intelligence, there is greater confidence in the design 
which is then used in wet-lab experiments. 
〇n top of the methods we have developed, some directions 
can reinforce the current approach. Whi le the funct ion of a pro-
tein is cri t ical to determine the fitness as a drug target, knowing 
the interacting elements is also important. There are data on 
interacting proteins housed on separate servers so i t is diff icult 
to gather them together. In addition, the latest discoveries are 
found l i terature but may not appear on any public databases. 
I t is viable to produce an algori thm to perform l i terature min-
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ing and piece together using standardised annotat ion such as 
Gene Ontology. Regarding the design of drug, the composition 
of drug is not l imi ted to small compound but short segments of 
protein. The design of such segments is beneficial as i t can raise 
natural immune response and have lower side effect than their 
compound variants. 
• End of chapter. 
Appendix A 
Glossary 
Alignment (n. bioinformatics) 
a way of arranging the sequence of DNA, R N A or Proteins 
to identi fy region of similari ty that may be a consequence of 
functional, structural, or evolutionary relationships between the 
sequences. 
Amino Acid(n. chemistry) 
any substances that combine to form the basic structure of 
Proteins. 
Bacteria(n. [pi.]) 
the simplest and smallest forms of life. Bacteria exist in large 
numbers in air, water and soil, and also in l iv ing and dead crea-
tures and plants, and are often a cause of disease. 
Binding Site(n. biochemistry) 
a region on a Protein, DNA, or R N A to which specific other 
molecules and ions form a chemical bond. 
Bioinformatics(n.) 
the retrieval and analysis of biochemical and biological data 
using mathematics and computer science, as in the study of 
genomes. 
184 
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Classification(n.) 
the act or process of pu t t ing people or things into a group or 
class. 
Cleft(n.) 
a natural opening or crack, for example in the ground or in 
rock, or in a person's chin. 
Chister(7z.) 
a group of things of the same type that appear close together. 
Conformation(n. formal) 
the way in which something is formed; the structure of some-
thing, especially an animal. 
Cliration(n. process) 
a process of establishing and developing long term reposi-
tories of digi tal assets for current and future reference by re-
searchers, scientists, historians and scholars. 
Data Cleansing(n. computing) 
a process of detecting and correcting corrupt or inaccurate 
records from a record set, table or database. 
Data Mining(n. computing) 
looking at large amounts of information that has been col-
lected on a computer and using i t to provide new information. 
Docking(n. biochemistry) 
a method which predicts the preferred orientation of one 
molecule to a second when bound to each other to form a stable 
complex. 
Drug(n.) 
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a substance used as a medicine or used in a medicine. 
EfBcacy(n. formal) synonym to effectiveness 
the abi l i ty of something, especially a drug or a medical treat-
ment, to produce the results that are wanted 
F-ineasure(n. statistics) synonym to F1 score 
a measure of test's accurarcy w i th its best value at 1 and 
worst value at 0 
Hydrophobic(a 办） 
extreme fear of water. 
Intervene(?；.) 
to become involved in a situation in order to improve or help 
i t . 
biochemistry) 
a molecule, as an antibody, hormone, or drug, that binds to 
a receptor 
chemistry) 
the smallest unit , consisting of a group of atoms, into which a 
substance can be divded without a change in its chemical nature. 
chemistry) 
a chemical consisting of two or more Amino Acids joined to-
gether 
ProteinO.) 
a natural substance found in meat, eggs, fish, some vegeta-
bles, etc. There are many different proteins and they are an 
essential part of what humans and animals eat to help them 
grow and stay healthy. 
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biology) 
a sense organ or nerve ending in the body that reacts to 
changes such as heat or cold and makes the body react in a 
part icular way. 
Sequence(认 biology) 
to identi fy the order in whcih a set of genes or parts of 
molecules are arranged. 
Small Molecule(n. 
biochemistry) 
a low weight organic compound which binds w i t h high aff inity 
to a biopolymer such as protein, nucleic acid, or polysaccharide 
and in addit ion alters the act iv i ty or funct ion of the biopolymer. 
Stere0SC0py(n.) synonym to 3D 
a picture or photograph that is made so that you see the 




the art i f ic ial product ion of a substance that is present natu-
ral ly in animals and plants. 
Virtual Reality(n.) 
images created by a computer that appear to surround the 
person looking at them and seem almost real 
Virus(n.) 
a l iv ing thing, too small to be seen wi thout a microscpe, that 
causes infectious disease in people, animals and plants. 
• End of chapter. 
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